<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 /Users/grace/grobid-0.6.1/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Are We Ready To Stratify Treatment for Diffuse Large B-Cell Lymphoma Using Molecular Hallmarks?</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sarah</forename><surname>Barton</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Medicine</orgName>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Eliza</forename><forename type="middle">A</forename><surname>Hawkes</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Medicine</orgName>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Andrew</forename><surname>Wotherspoon</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of Histopathology</orgName>
								<orgName type="institution">Royal Marsden Hospital</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author role="corresp">
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>M.D</roleName><forename type="first">David</forename><surname>Cunningham</surname></persName>
							<email>david.cunningham@rmh.nhs.uk</email>
							<affiliation key="aff0">
								<orgName type="department">Department of Medicine</orgName>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Oncologist</forename><forename type="middle">®</forename><surname>Lymphoma</surname></persName>
						</author>
						<author>
							<affiliation key="aff2">
								<orgName type="department">Department of Medicine</orgName>
								<orgName type="institution">Royal Marsden Hospital</orgName>
								<address>
									<addrLine>Downs Road</addrLine>
									<postCode>SM2 5PT</postCode>
									<settlement>Sutton</settlement>
									<region>Surrey</region>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Are We Ready To Stratify Treatment for Diffuse Large B-Cell Lymphoma Using Molecular Hallmarks?</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="DOI">10.1634/theoncologist.2012-0218</idno>
					<note type="submission">Received May 23, 2012; accepted for publication September 4, 2012; first published online in The Oncologist Express on October 18, 2012. ©AlphaMed Press</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.6.1" ident="GROBID" when="2021-09-14T02:48+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Lymphoma, large B-cell, diffuse • Gene expression profiling • Molecular targeted therapy • Drug therapy • Immunohistochemistry • Phenotype Disclosures: David Cunningham: Roche, Amgen (C/A)</term>
					<term>Roche, Merck, Amgen (RF). The other authors indicated no financial relationships. Section Editors: George P. Canellos: Celgene Business Advisory Board (C/A) Reviewer &quot;A&quot;: None Reviewer &quot;B&quot;: Gilead Sciences, Allos Therapeutics, Algeta, Millennium, Genentech, Chesapeake Biotech (C/A)</term>
					<term>Roche (H) Reviewer &quot;C&quot;: NIH-RO1 grant (RF)</term>
				</keywords>
			</textClass>
			<abstract>
				<p>After completing this course, the reader will be able to: 1. Describe the oncogenic drivers in DLBCL, especially those that have recently been identified, and how they relate to the oncogenic DLBCL subtypes. 2. Describe the prognostic and potentially predictive implications of DLBCL COO subtype for chemotherapy and rituximab. 3. Outline the evidence for novel targeted therapies and therapeutic strategies in DLBCL, how they may be stratified by DLBCL subtype or to specific tumor molecular features, and how these strategies can be incorporated into current treatment paradigms and prospective clinical trial design.</p>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>INTRODUCTION</head><p>There is a spectrum of malignant lymphoma composed of large B cells. The majority fall into the category of diffuse large Bcell lymphoma (DLBCL), which is the subject of this review. DLBCL comprises 30%-40% of adult lymphomas, with an incidence of around 8 cases per 100,000 <ref type="bibr" target="#b0">[1,</ref><ref type="bibr" target="#b1">2]</ref>. Although many patients with DLBCL achieve long-term remission, approximately a third of patients relapse after first-line rituximabchemotherapy regimens, with up to 30% eventually dying of their disease <ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b4">[5]</ref><ref type="bibr" target="#b5">[6]</ref><ref type="bibr" target="#b6">[7]</ref><ref type="bibr" target="#b7">[8]</ref><ref type="bibr" target="#b8">[9]</ref><ref type="bibr" target="#b9">[10]</ref>. The most established prognostic algorithm is the International Prognostic Index, which is based on clinical and biochemical parameters <ref type="bibr" target="#b10">[11]</ref>. More recently, as with solid organ malignancies <ref type="bibr" target="#b11">[12]</ref>, there has been a shift towards incorporating tumor molecular profiling into prognostication and treatment stratification for DLBCL.</p><p>With the advent of newer technologies, the heterogeneity in clinical outcome can be increasingly attributed to DLBCL tumor biology. Pivotal studies measured gene expression using cDNA microarrays <ref type="bibr" target="#b12">[13]</ref><ref type="bibr" target="#b13">[14]</ref><ref type="bibr" target="#b14">[15]</ref> or oligonucleotide microarrays <ref type="bibr" target="#b15">[16,</ref><ref type="bibr" target="#b16">17]</ref> to create molecular signatures characterizing individual DLBCL phenotypes. Next-generation sequencing is also revealing previously unknown pathogenic genetic alterations <ref type="bibr">[18 -21]</ref>. The most well-validated of the molecular phenotype classification schemas is that defining DLBCL as being representative of its cell of origin (COO) <ref type="bibr" target="#b12">[13,</ref><ref type="bibr" target="#b13">14,</ref><ref type="bibr">18]</ref>. Using this method, approximately 50% of DLBCL are classified as germinal center B-cell (GCB) subtype, around 30% are classified as the poorer prognosis activated B-cell (ABC) subtype, and the remaining 20% of DLBCL are unclassifiable, in which case they are commonly grouped with the ABC subtype as "non-GCB" <ref type="bibr" target="#b13">[14,</ref><ref type="bibr" target="#b14">15,</ref><ref type="bibr" target="#b21">22]</ref>.</p><p>This review aims to discuss established and emerging molecular hallmarks, recent developments in therapeutic strategy based on molecular phenotype, and how best to incorporate current knowledge into clinical practice in DLBCL.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>MOLECULAR METHODS OF CLASSIFICATION OF DLBCL</head><p>Initial studies by the Lymphoma/Leukemia Molecular Profiling Project in the early 2000s that delineated DLBCL subtypes according to ontogenic phenotype performed gene expression profiling (GEP) on DLBCL pretreatment biopsies with the unsupervised method of hierarchical clustering (grouping according to signature similarity) to construct "lymphochip" cDNA microarrays <ref type="bibr" target="#b12">[13,</ref><ref type="bibr" target="#b13">14]</ref>. GCB-DLBCL was characterized by genes expressed in normal germinal-center B cells, whereas ABC-DLBCL was typified by genes expressed during activation of peripheral blood B cells <ref type="bibr" target="#b12">[13]</ref>. The classification was changed to include a third unclassified group (type 3) <ref type="bibr" target="#b13">[14]</ref> and further refined using statistical methods to resolve differences in between microarray platforms <ref type="bibr" target="#b14">[15]</ref>. The investigators also proposed an alternative means of DLBCL classification based on both tumor microenvironment and intrinsic tumor characteristics <ref type="bibr" target="#b13">[14,</ref><ref type="bibr" target="#b21">22]</ref>.</p><p>A separate research group concurrently profiled gene expression using an oligonucleotide microarray platform (Affymetrix) with a supervised clustering method to divide DLBCL into subtypes based on tumor molecular features associated with cure or refractoriness to chemotherapy <ref type="bibr" target="#b15">[16]</ref>. Prominently overexpressed genes were NOR1, which was associated with cure, and PDE4B and PKC␤, both associated with refractory disease-the latter being a key component of the BCR and NF-B signaling pathways <ref type="bibr" target="#b15">[16,</ref><ref type="bibr" target="#b22">23]</ref>. These authors found no difference in prognosis between COO subtypes using the classification of Alizadeh et al. <ref type="bibr" target="#b12">[13]</ref>; however, on subsequent reanalysis of the material with refinement in COO phenotype definition, the difference in prognosis was evident <ref type="table" target="#tab_0">(Table 1)</ref>  <ref type="bibr" target="#b14">[15]</ref>. A further study by this group used multiple unsupervised clustering methods in defining three DLBCL subtypes: OxPhos (oxidative phosphorylation), BCR/proliferation (activation of the BCR signaling cascade), and HR (presence of markers of T-cell mediated immune response) <ref type="bibr" target="#b16">[17]</ref>.</p><p>Undoubtedly the various methods of defining DLBCL molecular phenotypes have contributed to knowledge of dysregulated pathways and potential therapeutic targets. However, lack of standardization, even within the COO phenotype definition described by the same group of authors, is an obstacle to broader clinical application. Although the GEP COO phenotype classification is the best verified as a predictor of prognosis in DLBCL <ref type="bibr" target="#b13">[14,</ref><ref type="bibr" target="#b21">22]</ref>, to date independent validation has been within small retrospective analyses <ref type="bibr">[24 -26]</ref>, with large-scale prospective clinical validation awaited.</p><p>The aforementioned studies have required fresh frozen tumor tissue samples on which to perform transcriptional profiling. This is prohibitive to wider use of GEP, as diagnostic biopsies are predominantly stored as formalin-fixed paraffinembedded (FFPE) tissue. However, advances in technology have now permitted GEP to be successfully performed on mRNA in FFPE tissue <ref type="bibr" target="#b26">[27]</ref>, with reported high accuracy in defining COO phenotype compared to fresh frozen tissue <ref type="bibr" target="#b27">[28,</ref><ref type="bibr" target="#b28">29]</ref>, although this data requires further verification.</p><p>Very recently, the exciting new technology of next-generation sequencing has enabled dramatic advances in understanding of the pathogenesis of DLBCL to be made in a short period of time through comprehensive unbiased interrogation of the DLBCL genome and transcriptome <ref type="bibr">[18 -21]</ref>. These methods have already revealed multiple functionally relevant mutations with a significant potential to lead to innovations in therapeutic strategy.</p><p>Barton, Hawkes, Wotherspoon et al.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>IMMUNOHISTOCHEMICAL METHODS OF CLASSIFICATION OF DLBCL</head><p>Although GEP is the standard method of evaluating DLBCL COO phenotype, it is currently costly, time consuming, and in-accessible for many centers. Hence, immunohistochemistry (IHC) algorithms were developed. The Hans algorithm <ref type="bibr" target="#b29">[30]</ref> stratifies cases as GCB or non-GCB according to protein expression of CD10, BCL-6, and MUM1. The algorithm is prog- nostic and correlates with GEP-defined subtype in approximately 80% of cases <ref type="bibr" target="#b29">[30]</ref>. Subsequent IHC algorithms with minor modifications have been developed <ref type="bibr" target="#b25">[26,</ref><ref type="bibr" target="#b30">31]</ref>. The Choi algorithm incorporates FOXP1 and GCET1 <ref type="bibr" target="#b25">[26]</ref>, whereas the Tally method substitutes BCL6 for LMO2 <ref type="bibr" target="#b30">[31]</ref>. The three algorithms were recently compared to GEP in biopsy samples from 108 patients <ref type="bibr" target="#b31">[32]</ref>, with results favoring the Hans and Choi algorithms over Tally. The positive predictive value of these IHC classification methods for identifying GEPclassified COO ranged from 0.78 to 1.0, with sensitivity of 0.58 -0.83; the Tally method was the least sensitive. The Hans and Choi algorithms (but not the Tally algorithm) were significantly predictive of overall survival (OS) and progressionfree survival (PFS). Although accuracy is less than that of GEP and reproducibility is variable, particularly for BCL6 staining [33], IHC phenotype classification is more readily available and cost effective; hence, it has been more widely adopted both in clinical practice and prospective trial designs.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>MOLECULAR CHARACTERISTICS OF ABC CELL OF ORIGIN</head><p>ABC-DLBCL is frequently associated with constitutive activation of the NF-B pathway, resulting in enhanced cell proliferation and decreased apoptosis. NF-B pathway signaling occurs through dimerization of NF-B transcription factors in the cytoplasm, which migrate to activate transcription of target genes in the nucleus <ref type="bibr" target="#b32">[34,</ref><ref type="bibr" target="#b33">35]</ref>. Negative pathway regulation is controlled by IkB family members and reversed by IkB kinase (IKK) <ref type="bibr" target="#b32">[34]</ref>. Cell-line data using RNA interference (RNAi), retroviral transduction and small molecule inhibitors as methods of repressing the NF-B pathway show that ABC-DLBCL but not GCB-DLBCL is dependent on the NF-B pathway for survival <ref type="bibr">[34, 36 -37]</ref>. Mutations affecting the NF-B pathway are more frequent but not exclusively present in ABC-DLBCL <ref type="bibr" target="#b36">[38]</ref>.</p><p>An important source of NF-B pathway activation in ABC-DLBCL is alteration in genes encoding components of an upstream signaling complex involving CARD11, BCL10, and MALT1 (CBM complex) <ref type="bibr" target="#b33">[35]</ref><ref type="bibr" target="#b34">[36]</ref><ref type="bibr" target="#b37">39]</ref>, which also forms part of the BCR-signaling pathway <ref type="figure" target="#fig_0">(Fig. 1)</ref>. Missense mutations in CARD11 occur with higher frequency in ABC-DLBCL (10%-11%) compared to GCB-DLBCL (4%-7%) <ref type="bibr" target="#b33">[35,</ref><ref type="bibr" target="#b36">38]</ref>. CARD11 mutant but not wild-type proteins have been demonstrated to independently promote NF-B pathway stimulation when introduced into lymphoma cell lines, indicating oncogenic functionality <ref type="bibr" target="#b33">[35]</ref>. Furthermore, RNAi knockdown of CARD11 negatively modulates NF-B signaling and is selectively toxic to ABC-DLBCL cells <ref type="bibr" target="#b34">[36]</ref>.</p><p>Dysregulated B-cell-receptor (BCR) signaling initiated upstream of CARD11 also mediates constitutive NF-B pathway activity and is implicated in lymphomagenesis of CARD11 wild-type (WT) ABC-DLBCL <ref type="bibr" target="#b38">[40]</ref>. BCR-signaling is generated by ligand-induced receptor engagement and SRC family kinase phosphorylation of the CD79A and CD79B receptor subunits, leading to activation of spleen tyrosine kinase (SYK) and triggering of a downstream cascade including Bruton's ty- rosine kinase (BTK) <ref type="bibr" target="#b38">[40]</ref>. Antigenic stimulation of transient BCR-signaling is an essential physiological B-cell process <ref type="bibr" target="#b39">[41]</ref>; however, chronic-active BCR-signaling is pathogenetic, as evidenced by the selective lethality of RNAi knockdown of key BCR pathway components in CARD11 WT ABC-DLBCL cell lines <ref type="bibr" target="#b34">[36]</ref>. Specific mutations within the CD79B subunit that promote chronic active BCR signaling have also been demonstrated to occur in higher frequency in ABC-DLBCL than in GCB-DLBCL <ref type="bibr" target="#b38">[40]</ref>. A20 contributes to termination of NF-B pathway signaling and appears to have a tumour suppressor gene role <ref type="bibr" target="#b36">[38,</ref><ref type="bibr" target="#b40">42]</ref>. Inactivating mutations in A20 cause constitutive NF-B activity through failure to abort pathway signaling; they occur in approximately 25% of ABC-DLBCL but are rare in GCB-DLBCL <ref type="bibr" target="#b36">[38]</ref>.</p><p>Other pathogenic molecular characteristics that are more frequent and of selective functional significance in ABC-DLBCL, but not directly associated with the NF-B pathway, include 19q amplification, INK4a/ARF tumour-suppressor locus deletion, trisomy 3 <ref type="bibr" target="#b41">[43]</ref>, inactivation of tumor suppressor BLIMP1 (encoded by the PRDM1 gene) <ref type="bibr" target="#b42">[44,</ref><ref type="bibr" target="#b43">45]</ref>, and overexpression of PIM family serine/threonine kinases <ref type="bibr">[46]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>MOLECULAR CHARACTERISTICS OF GCB CELL OF ORIGIN</head><p>Two early GEP-identified recurring genetic alterations exclusive to GCB-DLBCL are the t(14;18) translocation in BCL-2 and C-REL amplification, which occur with a frequency of approximately 25% and 15%, respectively <ref type="bibr" target="#b13">[14,</ref><ref type="bibr" target="#b41">43]</ref>. The t(14;18) translocation causes expression of the antiapoptotic BCL-2 protein and is a hallmark of follicular lymphoma (FL), which also arises from the germinal center-perhaps explaining why transformed DLBCL in the setting of FL is frequently of the GCB subtype. BCL2 protein expression is common in both DLBCL subtypes [47], but there are conflicting data regarding the phenotype for which it has prognostic significance. Prerituximab studies using GEP showed that BCL-2 expression was negatively prognostic in patients with ABC-DLBCL but not GCB-DLBCL treated with cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) <ref type="bibr">[48,</ref><ref type="bibr">49]</ref>. However, in patients treated with CHOP plus rituximab (R-CHOP), the situation appears reversed; BCL-2 expression is associated with inferior prognosis in both IHC-defined [50] and GEPdefined [49, 51] GCB-DLBCL but not in ABC (or non-GCB) DLBCL.</p><p>Variation in the mechanism causing BCL-2 expression may explain this. In a recently presented study in 483 patients treated with R-CHOP, BCL-2 protein expression correlated with BCL-2 gains in ABC-DLBCL, which was non-prognostic, but correlated instead with the t(14;18) translocation in GCB-DLBCL, which was associated with inferior prognosis <ref type="bibr">[51]</ref>. However, in a smaller study of 144 patients, the t(14;18) translocation was not associated with survival outcomes in patients treated with R-CHOP for GEP-defined GCB-DLBCL, possibly due to lack of power <ref type="bibr">[47]</ref>. Further prospective clinical evaluation is necessary to clarify the role of the t(14;18) translocation as a biomarker in GCB-DLBCL. c-MYC oncogene rearrangements as detected by fluorescent in-situ hybridization (FISH) occur with a frequency of 6%-14% [52-55] in DLBCL; they appear to be more common in GCB-DLBCL using the <ref type="bibr">Hans</ref>  Exome sequencing analyses have recently revealed that mutations in genes involved in epigenetic processes are prominent lymphoma-promoting mechanisms <ref type="bibr">[18 -19, 21]</ref>. Inactivating mutations in key histone acetyltransferase (HAT) genes CREBBP and EP300 also occur commonly in DLBCL; they display probable haplo-insufficient tumor suppressor functionality and appear pathogenic by impeding p53 tumor suppressor activity and enhancing BCL6 oncogene activity <ref type="bibr" target="#b18">[19]</ref>. CREBBP mutations occur more frequently in GCB-DLBCL (32%) than in ABC/nonclassified DLBCL (13%) <ref type="bibr" target="#b18">[19]</ref>. EP300 mutations are rarer, but again occur more often in GCB-DLBCL and seldom coexist with CREBBP mutations <ref type="bibr" target="#b18">[19]</ref>.</p><p>Mutations in the mixed-lineage leukemia 2 (MLL2) gene occur in biopsy samples with frequency of 27% in GCB-DLBCL and 20% in ABC-DLBCL; the majority of these appear to be inactivating <ref type="bibr">[18,</ref><ref type="bibr" target="#b19">20]</ref>. MLL2 encodes a histone methyltransferase, which influences gene transcription <ref type="bibr">[18]</ref>. MLL2 appears to behave as a haploinsufficient tumor suppressor gene (modified by one allelic mutation only) <ref type="bibr">[18]</ref>. Mutations at codon 641 of histone methyltransferase gene EZH2 are almost exclusive to GCB-DLBCL, present in 14%-22% of cases <ref type="bibr">[18,</ref><ref type="bibr" target="#b44">[62]</ref><ref type="bibr" target="#b45">[63]</ref>. Other GEP-identified potential oncogenic drivers that are exclusive or almost exclusive to GCB-DLBCL are overexpression of the mir-17-92 microRNA cluster amplification in approximately 13% and PTEN deletion in 11% of cases <ref type="bibr" target="#b41">[43]</ref>.</p><p>TP53 mutations were reported to be negatively prognostic in IHC-defined GCB-DLBCL but not in non-GCB-DLBCL [64]. However, this result was not supported by a study using GEP, which failed to demonstrate a difference between subgroups <ref type="bibr" target="#b46">[65]</ref>. TP53 mutations can provoke activation of the antiapoptotic NF-B pathway, which may be more significant in GCB-DLBCL; in ABC-DLBCL, this pathway is already constitutively activated <ref type="bibr">[64,</ref><ref type="bibr" target="#b47">66]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>MOLECULAR CHARACTERISTICS SHARED BY GCB AND ABC CELL OF ORIGIN</head><p>The frequencies of other molecular alterations have either not been compared between the GCB or ABC phenotypes or are similar in both. Inactivating mutations leading to absence of expression of immune recognition molecules ␤2 microglobulin (␤2M) and CD58 have been identified in both GCB and ABC/nonclassified DLBCL (␤2M: 10%-15%; CD58: 6%-7%), indicating that cellular immune surveillance is another lymphomagenic mechanism [67].</p><p>BCL-6 cytogenetic rearrangements are common in DLBCL <ref type="bibr">[54]</ref>. There is conflicting data from studies using the Hans IHC criteria to define subtype with regard to whether these are more prevalent in non-GCB-DLBCL <ref type="bibr" target="#b48">[68]</ref> or are similar in both subtypes <ref type="bibr">[53,</ref><ref type="bibr">54]</ref>. Uddin et al. demonstrated that PI3K pathway signaling as assessed by pAKT IHC expression occurs with a frequency of 52% in DLBCL and may represent a therapeutic target; however, the results were not analyzed according to COO subtype <ref type="bibr" target="#b49">[69]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>THERAPEUTIC STRATEGY ACCORDING TO MOLECULAR PROFILE</head><p>The enhanced delineation of tumorigenesis in DLBCL, capturing and categorizing the heterogeneous pattern of genetic alterations, has the potential to move clinicians toward stratification of treatment for DLBCL according to COO and individualized tumor signature. This knowledge has led to development of novel targeted agents, as well as to questions relating to the best use of current chemotherapy-based strategies.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Predictive and Prognostic Utility of COO for Rituximab-Treated DLBCL</head><p>Pre-rituximab analyses demonstrated superior outcomes in GEP-defined GCB-DBCL compared to ABC-DLBCL in patients receiving first-line chemotherapy <ref type="bibr" target="#b12">[13]</ref><ref type="bibr" target="#b13">[14]</ref><ref type="bibr" target="#b14">[15]</ref>. Although a seminal study showed maintained prognostic differentiation by GEP-defined phenotype in patients treated with rituximab plus chemotherapy (R-chemotherapy) <ref type="bibr" target="#b21">[22]</ref>, retrospective analyses from large randomized controlled trials (RCTs) in R-chemotherapy-treated patients showed no significant difference in prognosis between IHC-defined ontogenic subtypes <ref type="bibr">[33,</ref><ref type="bibr" target="#b50">70]</ref>. This has led to the hypothesis that ABC-DLBCL may benefit more substantially from rituximab than GCB-DLBCL, and that COO may therefore have a role in prediction of benefit from rituximab <ref type="bibr" target="#b51">[71]</ref>, supported by the biological rationale of preclinical evidence of rituximab inhibiting the NF-KB pathway <ref type="bibr" target="#b52">[72]</ref>. However, a more likely reason for the observation of lack of evidence for COO as a prognostic biomarker in rituximab-treated patients is the inferior accuracy and reproducibility of IHC-classification methods compared with GEP <ref type="bibr" target="#b53">[73]</ref>, given that studies showing lack of prognostic utility are amongst those using IHC classification methods <ref type="bibr">[33, 70, 74 -76]</ref>.</p><p>Small retrospective studies in patients treated predominantly with R-CHOP using GEP COO classification continue to demonstrate superior prognosis for GCB compared to ABC-DLBCL in rituximab-treated patients <ref type="bibr" target="#b23">[24,</ref><ref type="bibr" target="#b24">25]</ref>. These findings require verification in prospective clinical trials designed with upfront stratification by GEP-defined ontogenic subtype. Evidence for the prognostic utility of the COO classification in clinical studies of patients with DLBCL treated with chemotherapy with or without rituximab is presented in <ref type="table" target="#tab_0">Table 1</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>GCB/ABC Subtype as a Predictive Biomarker for Chemotherapy</head><p>Evidence suggests that COO phenotype may be predictive of response to standard chemotherapy regimens. The phenotype of a subset of patients within the second-line CORAL (Collaborative Trial in Relapsed Aggressive Lymphoma) study (249 of 396 patients) [53] was retrospectively analyzed using IHC methods <ref type="bibr" target="#b29">[30]</ref>. IHC COO classification was validated by GEP in a small sample (n ϭ 39), with 75% concordance. Patients with Hans IHC-defined GCB-DLBCL in the R-DHAP (rituximab, dexamethasone, high-dose cytarabine, and cisplatin) arm had improved PFS compared with non-GCB (52% vs. 32%, p ϭ .01), but no difference between subtype was seen in the R-ICE (rituximab, ifosfamide, carboplatin, and etoposide) arm (31% vs. 27%, p ϭ .81), and OS was not significantly different between phenotype in either arm. In the small GEPdefined sample, GCB phenotype was also predictive of response to chemotherapy (3-year PFS: 100% for R-DHAP vs. 27% for R-ICE; p ϭ .01); however, ABC phenotype was not predictive <ref type="bibr">[53]</ref>. The study was not powered for comparison between phenotype. Although the authors propose that cytarabine may alter BCL-6 expression levels and facilitate p53 release as justification for the findings, they recognize that this unplanned, retrospective analysis of small subgroups can only be hypothesis generating.</p><p>Interstudy comparison has led to discussion of whether GCB-DLBCL may benefit more from nonanthracycline-based chemotherapy than from R-CHOP <ref type="bibr" target="#b21">[22,</ref><ref type="bibr">53]</ref>, because small single-arm phase II studies suggested improved outcome for DA-EPOCH-R (dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin and rituximab) in IHC-defined GCB-DLBCL <ref type="bibr" target="#b57">[77,</ref><ref type="bibr" target="#b58">78]</ref>, whereas retrospective IHC analyses of phase III clinical trials treating with CHOP with or without rituximab show no difference in outcome between GCB and non-GCB subtypes <ref type="bibr" target="#b21">[22,</ref><ref type="bibr" target="#b50">70]</ref>. Once again, the IHC classification methods used may mean that these data are unreliable and should be interpreted with caution. The results of a currently recruiting phase III RCT investigating the benefit of R-CHOP versus R-EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) that incorporates GEP (ClincalTrials.gov NCT 00118209) will be interesting. Further clinical evidence from trials incorporating prospective GEP-defined COO subtype stratification is necessary to clarify the role for COO as a predictive biomarker for specific chemotherapy.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>TARGETED THERAPY FOR DLBCL ACCORDING TO MOLECULAR CHARACTERISTICS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>NF-B: Protease Inhibitors</head><p>NF-B pathway targeting is logical therapeutic strategy in ABC-DLBCL because of its pivotal role in pathogenesis. In vitro research has demonstrated that inhibition of the NF-B pathway in ABC-DLBCL cells results in cell death <ref type="bibr" target="#b32">[34,</ref><ref type="bibr" target="#b35">37]</ref>. Bortezomib is a proteasome inhibitor with multiple actions <ref type="bibr" target="#b59">[79]</ref>, including prevention of breakdown of phosphorylated IB␣, resulting in NF-B pathway repression <ref type="bibr">[34, 76, 79 -80]</ref>. Bortezomib monotherapy appears to have no activity in DLBCL <ref type="bibr" target="#b56">[76]</ref>, but there is phase I/II trial evidence of efficacy in combination with chemotherapy <ref type="bibr">[76, 80 -81]</ref>. Bortezomib potentially acts synergistically with chemotherapy by negating the antiapoptotic, chemotherapy-resistance promoting effects of NF-B pathway signaling.</p><p>A small nonrandomised phase II study of 27 patients with relapsed/refractory (RR)-DLBCL evaluated bortezomib plus DA-EPOCH chemotherapy in ABC-DLBCL (n ϭ 12) versus GCB-DLBCL (n ϭ 15). Results demonstrated greater efficacy in ABC-DLBCL (overall response rate [ORR]: 83% vs. 13%, p Ͻ .001; median OS: 10.8 vs. 3.4 months; p ϭ .003) <ref type="bibr" target="#b56">[76]</ref>. Phenotype was classified in approximately half of patients by GEP plus IHC and in half by IHC (Hans) alone <ref type="bibr" target="#b56">[76]</ref>.</p><p>Another nonrandomised phase I/II study of 40 patients with DLBCL treated with first-line R-CHOP plus bortezomib found no difference in outcome between GCB and non-GCB subtype using the Hans algorithm (ORR: 88%; 2-year OS: 70%). The poorer prognosis associated with non-GCB subtype and the use of IHC alone in the latter study may contribute to the discrepancy <ref type="bibr" target="#b60">[80]</ref>.</p><p>Acknowledging limitations relating to the differing phenotype classification methods and small numbers, these data have led to larger-scale research. In the U.K., the currently recruiting REMoDLB phase III trial (ClinicalTrials. gov NCT01324596) of first-line treatment of DLBCL (planned n ϭ 940) is evaluating R-CHOP with and without bortezomib. Stratification is by COO molecular subtype incorporating an interim efficacy analysis, with a planned early stop in the GCB subgroup if bortezomib is not beneficial. A firstline U.S. phase II randomized trial is also currently recruiting, with plans to enroll 190 patients with non-GCB subtype. It will assess R-CHOP with and without bortezomib (ClinicalTrials. gov NCT00931918).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Immunomodulation: Lenalidomide</head><p>Lenalidomide, an oral immunomodulatory drug with proapoptotic and antiangiogenic properties, has demonstrated activity as monotherapy in RR-DLBCL <ref type="bibr" target="#b62">[82,</ref><ref type="bibr" target="#b63">83]</ref> and in dual combination with rituximab for elderly patients with RR-DLBCL <ref type="bibr" target="#b62">[82]</ref>. It was safely combined with R-CHOP first-line treatment with encouraging response rates <ref type="bibr" target="#b62">[82,</ref><ref type="bibr">84]</ref>.</p><p>Theoretically, lenalidomide may be preferentially effective in ABC-DLBCL due to preclinical evidence in cell lines demonstrating suppression of NF-B <ref type="bibr" target="#b64">[85,</ref><ref type="bibr" target="#b65">86]</ref>. In support of this hypothesis, a retrospective clinical study of 40 patients with RR-DLBCL who were treated with lenalidomide demonstrated an improved ORR in non-GCB compared to the GCB subtype (53% vs. 9%, p ϭ .006), using the Hans IHC classification <ref type="bibr" target="#b66">[87]</ref>.</p><p>Although these studies do not provide sufficient evidence to currently recommend stratifying treatment with lenalidomide by COO subtype, they have led to the hypothesis being tested in a randomized phase II/III trial, including patients with RR-DLBCL in third-line treatment line or who are unsuitable for transplantation. The study compares lenalidomide to the investigator's choice of cytotoxic monotherapy, with stratification for phenotype (GCB or non-GCB), again incorporating early analysis of efficacy according to subtype (ClinicalTrials. gov NCT01197560).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BCR Signaling: SYK Inhibitors</head><p>Given the evidence for the dependence of ABC-DLBCL upon BCR signaling for survival, particularly in CARD11 WT disease, targeting of the BCR-signaling pathway is a rational therapeutic strategy <ref type="bibr" target="#b33">[35]</ref>. Experiments in cell lines and primary DLBCLs have demonstrated that sensitivity to R406, an inhibitor of SYK, is associated with BCR signaling-related factors <ref type="bibr" target="#b67">[88]</ref>.</p><p>Fostamitinib, an oral SYK inhibitor and R406 prodrug, has shown activity as monotherapy in multiply-RR DLBCL (COO subtype not reported), with an ORR of 22% in a phase II study <ref type="bibr" target="#b68">[89]</ref>. Of 23 patients, complete remission was reported for one patient and partial remission for four patients. It is yet to be determined whether the preclinical findings will translate into greater efficacy for fostaminib in ABC-DLBCL than GCB-DLBCL in the clinical setting.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BCR Signaling: SRC and BTK Inhibitors</head><p>Bruton's tyrosine kinase (BTK) is a BCR-signaling pathway protein located upstream of CARD11, activated by SYK <ref type="bibr" target="#b38">[40]</ref>. It is a logical target for therapeutic intervention in ABC-DL-BCL given evidence that it is essential for survival in CARD11 WT cell lines <ref type="bibr" target="#b38">[40]</ref>. Preclinical experiments revealed that a small molecule irreversible inhibitor of BTK, PCI-32765, blocks BCR signaling <ref type="bibr" target="#b69">[90]</ref>; it is active in CARD11 WT but not in CARD11 MT ABC-DLBCL <ref type="bibr" target="#b70">[91]</ref>. PCI-32765 has been tested in a phase I trial in RR-DLBCL, with minimal toxicity and two of seven patients showing objective responses <ref type="bibr">[92]</ref>. The preliminary results of a small phase II study in RR-ABC-DLBCL reported achievement of complete response in two of eight patients treated with PCI-32765 monotherapy <ref type="bibr" target="#b71">[93]</ref>. Other PCI-32765 phase II studies are in progress and other BTK inhibitors are in early stages of development.</p><p>Dasatinib is an inhibitor of SRC family kinases and BTK <ref type="bibr" target="#b72">[94]</ref>. An early preclinical study found no difference in the activity of dasatinib between GCB and non-GCB cells using the Hans IHC classification <ref type="bibr" target="#b73">[95]</ref>. However, a subsequent preclinical study using GEP demonstrated that ABC-DLBCL cells dependent on BCR signaling were selectively sensitive to dasatinib, whereas BCR-independent ABC-DLBCL and GCB-DLBCL cells were insensitive <ref type="bibr" target="#b38">[40]</ref>. Because its targets are upstream of CARD11, dasatinib may also be more effective in CARD11 WT disease <ref type="bibr" target="#b38">[40]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>PKC␤ Inhibition</head><p>Enzastaurin is an oral inhibitor of protein kinase C␤ (PKC␤), which has the knock-on effects of PI3K/AKT and mTOR pathway inhibition <ref type="bibr" target="#b74">[96]</ref>. PKC␤ indirectly stimulates IKK activity, promoting constitutive NF-B signaling <ref type="bibr" target="#b75">[97]</ref>, so notionally it may be more effective in ABC-DLBCL. Enzastaurin shows activity in preclinical studies <ref type="bibr" target="#b76">[98,</ref><ref type="bibr" target="#b77">99]</ref>, and 4E-BP1 function has been identified as a potential biomarker <ref type="bibr" target="#b74">[96]</ref>.</p><p>A phase II study reported activity of enzastaurin monotherapy in RR-DLBCL (COO subtype unreported), with minimal toxicity and 4 of 55 patients achieving durable remissions <ref type="bibr" target="#b78">[100]</ref>. A phase III study assessing the benefit of enzastaurin in maintenance of remission after first-line R-CHOP in DLBCL has completed accrual and the results are awaited (ClinicalTrials.gov NCT00332202).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Epigenetic Strategies</head><p>The histone deacetylase inhibitor (HDACI) vorinostat has limited single-agent activity in DLBCL <ref type="bibr" target="#b79">[101]</ref>. However, the combination of HDACI pabinostat and hypomethylating agent decitabine is synergistic in DLBCL in preclinical studies <ref type="bibr" target="#b80">[102]</ref>. GEP analysis has revealed genes with altered methylation as a result of the combination drug therapy, such as VHL methylation, a known poor prognostic factor in DLBCL, which may be worthy of evaluation in clinical studies <ref type="bibr" target="#b80">[102,</ref><ref type="bibr" target="#b81">103]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Angiogenesis Inhibition</head><p>Continuing on from the recognition that the DLBCL stromal-2 phenotype has an abundance of vessels and angiogenic factors <ref type="bibr" target="#b21">[22]</ref>, VEGF-targeting with bevacizumab has been tested in DLBCL, although without evidence of benefit. A phase II trial in first-line treatment of DLBCL with bevacizumab plus R-CHOP was negative. Additionally, 30 of the 64 patients treated had serious adverse events, including increased gastrointestinal perforation and cardiac dysfunction <ref type="bibr">[104]</ref>. A phase III trial of R-CHOP with and without bevacizumab was stopped early due to an un-  <ref type="bibr" target="#b60">[80,</ref><ref type="bibr" target="#b83">107]</ref>, but clinical activity in DLBCL is yet to be demonstrated <ref type="bibr" target="#b84">[108]</ref>. Based on evidence of efficacy of mTOR inhibition in other types of lymphoma, oral everolimus, a selective mTORC1 inhibitor, has been tested in small nonrandomized phase I/II clinical trials for RR-DLBCL, with ORR of 30%-31% <ref type="bibr" target="#b85">[109,</ref><ref type="bibr" target="#b86">110]</ref>. There is phase II evidence for the activity of temsirolimus, another mTORC1 inhibitor, in RR-DLBCL, with ORR of 28% (n ϭ 32) <ref type="bibr" target="#b87">[111]</ref>. Dual-targeting strategies may have the potential to improve on single-agent efficacy by overcoming resistance mechanisms, such as escape signaling via mTORC2 <ref type="bibr" target="#b85">[109,</ref><ref type="bibr">112]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Ras/Raf/MEK/ERK Pathway Inhibition</head><p>Oral tipifarnib is a farnesyltransferase inhibitor that has multiple effects. A central mechanism of action is inhibition of the Ras signaling pathway, leading to upregulation of the proapoptotic BH-3 protein BIM <ref type="bibr" target="#b88">[113,</ref><ref type="bibr" target="#b89">114]</ref>. A phase II trial including 37 patients with RR-DLBCL treated with tipifarnib reported ORR of 17% <ref type="bibr" target="#b88">[113]</ref>. Upregulation of BIM in association with low BCL-2 expression (BCL-2 inhibits BIM) was predictive for response <ref type="bibr" target="#b88">[113]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Other Potential Targeted Therapies in Early Development</head><p>Many other potential therapies remain under early evaluation, including JAK1/JAK2 inhibitors <ref type="bibr" target="#b90">[115]</ref>, MDM2 inhibitor nutlin-3a <ref type="bibr" target="#b91">[116]</ref>, AKT inhibitor MK-2206 <ref type="bibr" target="#b81">[103]</ref>, a small-molecule MEK inhibitor [117], CHK1/2 inhibitor PF-0477736 <ref type="bibr" target="#b93">[118]</ref>, AAK inhibitor MLN8237 <ref type="bibr" target="#b95">[119]</ref>, anti-CD 22 immunoconjugate inotuzumab ozogamicin <ref type="bibr" target="#b97">[120]</ref>, CD19 targeting <ref type="bibr" target="#b98">[121,</ref><ref type="bibr" target="#b99">122]</ref>, and type II anti-CD20 monoclonal antibody GA-101 <ref type="bibr" target="#b100">[123]</ref>. A selection of key emerging targeted therapies are summarized in <ref type="table" target="#tab_2">Table 2</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Dual-Targeting Strategies</head><p>There is no single driving mutation in DLBCL; hence, a multitargeted strategy is required. Several combinations of targeted agents are being evaluated prospectively in early-phase trials due to promising synergistic activity, such as sorafenib (an inhibitor of Raf/VEGF) plus everolimus (ClinicalTrials. gov NCT00474929) <ref type="bibr" target="#b101">[124]</ref>, everolimus plus rituximab <ref type="bibr" target="#b103">[125]</ref>, and pabinostat plus everolimus <ref type="bibr" target="#b104">[126]</ref>. Other combinations with preclinical evidence of synergy include NVP-BEZ235 (a dual PI3K/mTOR inhibitor) plus enzastaurin <ref type="bibr" target="#b105">[127]</ref>, lenalidomide and the BTK inhibitor ibrutinib <ref type="bibr" target="#b65">[86]</ref>, and the BCL-2 inhibitor obatoclax plus proteosome inhibitor carfilzomib <ref type="bibr" target="#b106">[128]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>FUTURE DIRECTIONS</head><p>It is important to recognize that the majority of these novel drugs are currently in early stages of development. Many of the targets at which these therapies are directed have been developed based on preclinical science in cell lines rather than in primary tumor specimens, making it difficult to be certain that the dyregulated pathways identified represent authentic oncogenic driving mechanisms in DLBCL. At the time of writing, the reported prospective clinical studies have contained small nonrandomized populations, and clearly further verification of their efficacy is required.</p><p>To truly personalize medicine for DLBCL, not only does efficacy of these novel agents need validation, but their role needs to be established within the current treatment paradigm. Adaptive trial designs with enriched patient populations and markers of early response, marrying translational and clinical knowledge, must remain a key focus for future research. Preplanned subgroup analyses and stratification should be based on not only clinical characteristics but also on tumor biology.</p><p>Current treatment paradigms do not distinguish between COO phenotype, and this can be readily justified. Several large analyses have shown no difference in prognosis between phenotypes using IHC classification methods, indicating a lack of precision and reliability that dissuades against routine clinical use. GEP has superior accuracy in classifying DLBCL into COO subtypes with different biology and prognosis. It holds promise for future clinical application once issues of availability, cost, preference for analyses to be performed on fresh frozen tissue, lack of standardization in COO phenotype classification methods, and lack of prospective randomized clinical evidence validating its use can be overcome.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CONCLUSION</head><p>Biologically distinct ontogenic phenotypes with distinct pathogenic driving mechanisms are now well recognized in DLBCL, offering potential opportunities to individualize therapy based on molecular characteristics. Although GEP is more accurate than IHC in determining COO, it is associated with issues of accessibility, methodology, and lack of robust evidence. Therefore, a change in clinical practice with stratification of treatment according to molecular hallmarks is not presently vindicated. However, given the prognostic and therapeutic implications, prudence is suggested with respect to recognizing GEP-determined COO and key molecular targets within all future therapeutic trial designs.</p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1 .</head><label>1</label><figDesc>Pathogenetic signaling pathways in diffuse large B-cell lymphoma (DLBCL) and sites for exploitation with targeted therapy. Oncogenic intracellular signal transduction pathways for DLBCL including BCR signaling, RAS/RAF/MEK/MAPK, PI3K/AKT/ mTOR, and NF-B pathways are displayed. Tumor suppressors PTEN and A20 are depicted in pink, with downward arrows. Molecular targeted therapy in DLBCL and their sites of action are indicated.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 .</head><label>1</label><figDesc>Selected studies of prognosis of diffuse large B-cell lymphoma subtype defined by either immunohistochemistry or gene expression profiling</figDesc><table><row><cell></cell><cell>Method of phenotype</cell><cell></cell><cell></cell><cell>n of patients evaluated for</cell><cell>Outcome according to</cell><cell></cell></row><row><cell>Reference</cell><cell>classification</cell><cell>Analysis</cell><cell>Treatment received</cell><cell>phenotype</cell><cell>phenotype</cell><cell>Prognostic?</cell></row><row><cell>Alizadeh et al.[13]</cell><cell>GEP</cell><cell>Retrospective analysis</cell><cell cols="2">Multiagent chemotherapy 40 (19 GCB, 12 ABC)</cell><cell>Higher probability of OS for</cell><cell>Yes</cell></row><row><cell></cell><cell></cell><cell>on pretreatment</cell><cell></cell><cell></cell><cell>GCB vs. ABC (p Ͻ .01);</cell><cell></cell></row><row><cell></cell><cell></cell><cell>DLBCL biopsy</cell><cell></cell><cell></cell><cell>5-yr OS: GCB, 76%; ABC,</cell><cell></cell></row><row><cell></cell><cell></cell><cell>samples</cell><cell></cell><cell></cell><cell>16%</cell><cell></cell></row><row><cell>Rosenwald et al. [14]</cell><cell>GEP</cell><cell>Retrospective analysis</cell><cell>Multiagent chemotherapy</cell><cell>240 (115 GCB, 73 ABC, 52</cell><cell>Higher probability of OS for</cell><cell>Yes</cell></row><row><cell></cell><cell></cell><cell>on pre-treatment</cell><cell>(anthracycline based)</cell><cell>type 3)</cell><cell>GCB vs. ABC (p Ͻ .001); 5</cell><cell></cell></row><row><cell></cell><cell></cell><cell>DLBCL biopsy</cell><cell></cell><cell></cell><cell>yr OS: GCB, 60%; ABC,</cell><cell></cell></row><row><cell></cell><cell></cell><cell>samples</cell><cell></cell><cell></cell><cell>35%; type 3, 39%</cell><cell></cell></row><row><cell>Wright et al. [15]</cell><cell>GEP</cell><cell>Retrospective analysis</cell><cell cols="2">Multiagent chemotherapy 58 (31 GCB, 17 ABC)</cell><cell>Higher probability of OS for</cell><cell>Yes</cell></row><row><cell></cell><cell></cell><cell>on pretreatment</cell><cell></cell><cell></cell><cell>GCB vs. ABC (p ϭ .0053);</cell><cell></cell></row><row><cell></cell><cell></cell><cell>DLBCL biopsy</cell><cell></cell><cell></cell><cell>5-yr OS: GCB, 62%; ABC,</cell><cell></cell></row><row><cell></cell><cell></cell><cell>samples</cell><cell></cell><cell></cell><cell>26%</cell><cell></cell></row><row><cell>Hans et al. [30]</cell><cell>IHC (Hans)</cell><cell>Retrospective analysis</cell><cell>Not specified</cell><cell>(64 GCB, 88 non-GCB)</cell><cell>Higher probability of OS for</cell><cell>Yes</cell></row><row><cell></cell><cell></cell><cell>on pretreatment</cell><cell></cell><cell></cell><cell>GCB vs. non-GCB (p Ͻ</cell><cell></cell></row><row><cell></cell><cell></cell><cell>DLBCL biopsy</cell><cell></cell><cell></cell><cell>.001); 5-yr OS: GCB, 76%;</cell><cell></cell></row><row><cell></cell><cell></cell><cell>samples</cell><cell></cell><cell></cell><cell>non-GCB 34%</cell><cell></cell></row><row><cell>Nyman et al. [74]</cell><cell>IHC (Hans)</cell><cell>Retrospective analysis</cell><cell>R-CHOP-like (90) and</cell><cell>194 (97 GCB, 97 non-GCB)</cell><cell>R-CHOP-like 27-mo OS:</cell><cell>Yes, in CHOP-like</cell></row><row><cell></cell><cell></cell><cell>on pretreatment</cell><cell>CHOP-like (104)</cell><cell></cell><cell>77% GCB vs. 75% non-</cell><cell>No, in R-CHOP-</cell></row><row><cell></cell><cell></cell><cell>DLBCL biopsy</cell><cell></cell><cell></cell><cell>GCB; CHOP-like 27 month</cell><cell>like</cell></row><row><cell></cell><cell></cell><cell>samples</cell><cell></cell><cell></cell><cell>OS: 70% GCB vs. 47% non-</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>GCB (p ϭ .012)</cell><cell></cell></row><row><cell>Lenz et al. [22]</cell><cell>GEP</cell><cell>Retrospective analysis</cell><cell>R-CHOP (CHOP-treated</cell><cell>233 (107 GCB, 93 ABC, 33</cell><cell>Higher probability of OS for</cell><cell>Yes</cell></row><row><cell></cell><cell></cell><cell>on pretreatment DLBCL biopsy samples</cell><cell>patients not included in prognosis analysis)</cell><cell>unclassified)</cell><cell>GCB vs. ABC (p Ͻ .001); 5-yr OS: GCB, ϳ80%; ABC, ϳ50%</cell><cell></cell></row><row><cell>Jais et al. [24]</cell><cell>GEP</cell><cell>Retrospective analysis</cell><cell>R-CHOP</cell><cell>97 total; 67 R-CHOP treated</cell><cell>Higher probability of OS for</cell><cell>Yes</cell></row><row><cell></cell><cell></cell><cell>on pretreatment</cell><cell></cell><cell>(25 GCB, 42 ABC)</cell><cell>GCB vs. ABC (HR: 0.18;</cell><cell></cell></row><row><cell></cell><cell></cell><cell>DLBCL biopsy samples, 52/97 from a phase II RCT</cell><cell></cell><cell></cell><cell>CI: 0.04-0.76; p ϭ .02); 5-yr OS: GCB, ϳ93%; ABC, ϳ48%</cell><cell></cell></row><row><cell>Wilson et al. [78]</cell><cell>IHC (Hans)</cell><cell>Retrospective analysis</cell><cell>DA-EPOCH-R</cell><cell>71 (34 GCB, 17 non-GCB)</cell><cell>No significant difference in</cell><cell>No</cell></row><row><cell></cell><cell></cell><cell>on pretreatment</cell><cell></cell><cell></cell><cell>OS (p ϭ .059); 5-yr OS:</cell><cell></cell></row><row><cell></cell><cell></cell><cell>DLBCL biopsy</cell><cell></cell><cell></cell><cell>GCB, 84%; non-GCB, 64%</cell><cell></cell></row><row><cell></cell><cell></cell><cell>samples from a phase</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>II trial</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Fu et al. [75]</cell><cell>IHC (Hans)</cell><cell>Retrospective analysis</cell><cell>R-CHOP (131) and</cell><cell>253 total (121 GCB, 186 non-</cell><cell>Higher probability of OS for</cell><cell>Yes</cell></row><row><cell></cell><cell></cell><cell>on pretreatment</cell><cell>CHOP (112, not included</cell><cell>GCB); 131 R-CHOP</cell><cell>GCB vs. non-GCB (p ϭ</cell><cell></cell></row><row><cell></cell><cell></cell><cell>DLBCL biopsy</cell><cell>in prognostic assessment)</cell><cell></cell><cell>.032); 3-yr OS: GCB, 85%;</cell><cell></cell></row><row><cell></cell><cell></cell><cell>samples</cell><cell></cell><cell></cell><cell>non-GCB, 69%</cell><cell></cell></row><row><cell>Choi et al. [26]</cell><cell>IHC (Choi) and GEP</cell><cell>Retrospective analysis</cell><cell>R-CHOP</cell><cell>63 validation set (37 GCB, 26</cell><cell>IHC: Higher probability of</cell><cell>Yes</cell></row><row><cell></cell><cell></cell><cell>on pretreatment</cell><cell></cell><cell>ABC)</cell><cell>OS for GCB vs. ABC (p Ͻ</cell><cell></cell></row><row><cell></cell><cell></cell><cell>DLBCL biopsy</cell><cell></cell><cell></cell><cell>.001); 3-yr OS: GCB, 87%;</cell><cell></cell></row><row><cell></cell><cell></cell><cell>samples</cell><cell></cell><cell></cell><cell>ABC, 44%</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>GEP: Higher probability of</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>OS for GCB vs. ABC (p Ͻ</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>.001); 3-yr OS: GCB, 92%;</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>ABC, 44%</cell><cell></cell></row><row><cell cols="2">Gutierrez-Garcia et al. [25] IHC (Hans, Choi,</cell><cell>Retrospective analysis</cell><cell>R-chemotherapy</cell><cell>157 (135 IHC, 52 GEP)</cell><cell>IHC: No significant OS</cell><cell>Yes, in GEP</cell></row><row><cell></cell><cell>Tally, Colomo, Muris)</cell><cell>on pretreatment</cell><cell></cell><cell></cell><cell>difference in any IHC</cell><cell>No, in IHC</cell></row><row><cell></cell><cell>and GEP</cell><cell>DLBCL biopsy</cell><cell></cell><cell></cell><cell>method</cell><cell></cell></row><row><cell></cell><cell></cell><cell>samples</cell><cell></cell><cell></cell><cell>GEP: Higher probability of</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>OS for GCB vs. ABC (p ϭ .03); 3-yr OS: GCB, ϳ85%; ABC, ϳ60%</cell><cell></cell></row><row><cell>Cunningham et al. [70]</cell><cell>IHC (Hans)</cell><cell>Retrospective analysis</cell><cell>R-CHOP</cell><cell>1080 total; 560 tissue evaluable</cell><cell>No difference in 2-yr OS</cell><cell>No</cell></row><row><cell></cell><cell></cell><cell>on pretreatment</cell><cell></cell><cell>(289 GCB, 271 non-GCB)</cell><cell>(p ϭ .2082)</cell><cell></cell></row><row><cell></cell><cell></cell><cell>DLBCL biopsy</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>samples from a</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>prospective phase III</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>RCT</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Wilson et al. [77]</cell><cell>IHC (Hans)</cell><cell>Retrospective analysis</cell><cell>DA-EPOCH-R</cell><cell>52</cell><cell>Higher probability of OS for</cell><cell>Yes</cell></row><row><cell></cell><cell></cell><cell>on pretreatment</cell><cell></cell><cell></cell><cell>GCB vs. non-GCB (p ϭ</cell><cell></cell></row><row><cell></cell><cell></cell><cell>DLBCL biopsy</cell><cell></cell><cell></cell><cell>.04); 5-yr OS: GCB, 94%;</cell><cell></cell></row><row><cell></cell><cell></cell><cell>samples from a phase</cell><cell></cell><cell></cell><cell>non-GCB, 68%</cell><cell></cell></row><row><cell></cell><cell></cell><cell>II trial</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Ott et al. [33]</cell><cell>IHC (Hans)</cell><cell>Retrospective analysis on pretreatment</cell><cell>CHOP Ϯ R</cell><cell>(166 GCB, 186 non-GCB) 949 total; 506 tissue evaluable</cell><cell>of OS (p ϭ .514) No difference in probability</cell><cell>No</cell></row><row><cell></cell><cell></cell><cell>DLBCL biopsy</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>samples from a</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>prospective phase III</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>RCT</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="7">Abbreviations: ABC, activated B-cell; CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone; CI,</cell></row><row><cell cols="7">confidence interval; DA-EPOCH, dose-adjusted etoposide, prednisolone, vincristine, cyclophosphamide, doxorubicin;</cell></row><row><cell cols="7">DLBCL, diffuse large B-cell lymphoma; GCB, germinal center B-cell; GEP, gene expression profiling; HR, hazard ratio;</cell></row><row><cell cols="6">IHC, immunohistochemistry; OS, overall survival; R, rituximab; RCT, randomized controlled trial.</cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head></head><label></label><figDesc>IHC classification [52-53, 55-56], although an analysis using the Choi IHC algorithm is conflicting [57]. c-MYC rearrangements cause constitutive expression and dysfunction of the transcription controller c-myc, and they have been correlated with poor prognosis in patients treated with chemotherapy both with the addition of rituximab [53-55, 58 -59] and without [52, 56]. The "double-hit" gene rearrangement of both c-MYC and t(14;18) is associated with FL histologically transformed to DLBCL [60] and conveys additively inferior prognosis [54 -56]. High IHC expression of both BCL-2 and MYC is also associated with a poor prognosis [61].</figDesc><table /><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 2 .</head><label>2</label><figDesc>Selected clinical studies of targeted therapy in patients with diffuse large B-cell lymphoma subtype</figDesc><table><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>n of patients</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>Type of</cell><cell></cell><cell>evaluated for</cell><cell>Outcome in</cell><cell>Phenotypic</cell><cell></cell><cell></cell></row><row><cell>Therapy</cell><cell>Target</cell><cell>study</cell><cell>Indication</cell><cell>phenotype</cell><cell>DLBCL</cell><cell>efficacy</cell><cell>Toxicity</cell><cell>Reference</cell></row><row><cell>Bortezomib (ϩ DA-EPOCH)</cell><cell>NF-B</cell><cell>Phase II</cell><cell>Second-line DLBCL</cell><cell>27 (12 ABC, 15 GCB)</cell><cell>Median OS: 10.8 months in</cell><cell>(IHC ϩ GEP) ABC Ͼ GCB</cell><cell>(thrombocytopenia [G4 Cytopenias</cell><cell>Dunleavy et al. [76]</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>ABC vs. 3.4 in</cell><cell></cell><cell>15%]), febrile</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>GCB (p ϭ .003)</cell><cell></cell><cell>neutropenia (G3 20%), neuropathy (G3 Ն14%)</cell><cell></cell></row><row><cell>Bortezomib</cell><cell>NF-B</cell><cell>Phase I/II</cell><cell>First-line DLBCL/</cell><cell>32 (18 non-</cell><cell>2-yr PFS, 64%;</cell><cell>ABC ϭ GCB</cell><cell>Cytopenias, febrile</cell><cell>Ruan et al. [80]</cell></row><row><cell>(ϩR-CHOP)</cell><cell></cell><cell></cell><cell>mantle cell</cell><cell>GCB, 14</cell><cell>2-yr OS, 70%;</cell><cell>(IHC)</cell><cell>neutropenia (G3 17%),</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell>lymphoma</cell><cell>GCB)</cell><cell>no difference</cell><cell></cell><cell>infection/sepsis (G3</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>between ABC</cell><cell></cell><cell>20%), neuropathy</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>and GCB</cell><cell></cell><cell>(G3 4%)</cell><cell></cell></row><row><cell>Lenalidomide</cell><cell>NF-B,</cell><cell>Retrospective</cell><cell>RR-DLBCL,</cell><cell>40 DLBCL</cell><cell>ORR: 53% in</cell><cell>ABC Ͼ GCB</cell><cell>Not reported</cell><cell>Hernadez-Ilizaliturri</cell></row><row><cell></cell><cell>angiogenesis,</cell><cell>review</cell><cell>(heavily</cell><cell>(23 GCB, 17</cell><cell>ABC vs. 9% in</cell><cell>(IHC)</cell><cell></cell><cell>et al. [87]</cell></row><row><cell></cell><cell>TNF␣, T</cell><cell></cell><cell>pretreated)</cell><cell>non-GCB)</cell><cell>GCB (p ϭ</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>cells</cell><cell></cell><cell></cell><cell></cell><cell>.006); no</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>difference in</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>OS</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Fostamatinib</cell><cell>SYK, BCR</cell><cell>Phase I/II</cell><cell>RR-B-NHL</cell><cell>23 DLBCL</cell><cell>ORR: 22%</cell><cell>Not reported</cell><cell>Cytopenias, febrile</cell><cell>Friedberg et al. [89]</cell></row><row><cell></cell><cell>signaling</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>neutropenia (G3/4 4%),</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>hypertension (G3/4</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>6%), ALT rise (G3/4</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>4%)</cell><cell></cell></row><row><cell>PCI-32765</cell><cell>BTK, BCR</cell><cell>Phase I</cell><cell>RR B-cell</cell><cell>7 DLBCL</cell><cell>ORR 29%</cell><cell>Not reported</cell><cell>Modest cytopenias, no</cell><cell>Advani et al. [92]</cell></row><row><cell></cell><cell>signaling</cell><cell></cell><cell>malignancy</cell><cell></cell><cell></cell><cell></cell><cell>DLT, well tolerated</cell><cell></cell></row><row><cell>PCI-32765</cell><cell>BTK, BCR</cell><cell>Phase II</cell><cell>RR ABC DLBCL</cell><cell>8 DLBCL (of</cell><cell>ORR 25%</cell><cell>ABC (only ABC</cell><cell>Mild GI toxicity</cell><cell>Staudt et al. [93]</cell></row><row><cell></cell><cell>signaling</cell><cell></cell><cell></cell><cell>15 planned)</cell><cell></cell><cell>treated)</cell><cell></cell><cell></cell></row><row><cell>Enzastaurin</cell><cell>PKC␤</cell><cell>Phase II</cell><cell>RR DLBCL</cell><cell>55 DLBCL</cell><cell>15% FFP Ն4</cell><cell>Not reported</cell><cell>Fatigue, diarrhea,</cell><cell>Robertson et al.</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>cycles (28-day</cell><cell></cell><cell>nausea, vomiting</cell><cell>[100]</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>cycle duration);</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>7% FFP Ն20</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>cycles</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Bevacizumab</cell><cell>VEGF</cell><cell>Phase II</cell><cell>First-line DLBCL</cell><cell>64 DLBCL</cell><cell>2-yr PFS: 69%;</cell><cell>Not reported</cell><cell>GI perforation (G3 8%),</cell><cell>Stopeck et al. [104]</cell></row><row><cell>(ϩR-CHOP)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>2-yr OS: 79%;</cell><cell></cell><cell>cardiac dysfunction</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>did not meet</cell><cell></cell><cell>(G2/3 20%), arterial or</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>prespecified</cell><cell></cell><cell>venous thrombosis (G3</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>primary</cell><cell></cell><cell>8%), cytopenias</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>endpoint</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Everolimus</cell><cell>mTORC1</cell><cell>Phase II</cell><cell>RR aggressive</cell><cell>DLBCL</cell><cell>ORR: 30%</cell><cell>Not reported</cell><cell>Cytopenias (G3/4 55%),</cell><cell>Witzig et al. [109]</cell></row><row><cell></cell><cell></cell><cell></cell><cell>lymphoma</cell><cell></cell><cell></cell><cell></cell><cell>hyperglycemia (G3</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>8%), fatigue (G3 8%)</cell><cell></cell></row><row><cell>Everolimus ϩ</cell><cell>mTORC1,</cell><cell>Phase II</cell><cell>RR DLBCL,</cell><cell>25 DLBCL</cell><cell>ORR: 24%</cell><cell>Not reported</cell><cell>Cytopenias,</cell><cell>Barnes et al. [125]</cell></row><row><cell>rituximab</cell><cell>CD-20</cell><cell></cell><cell>heavily pretreated</cell><cell></cell><cell></cell><cell></cell><cell>hypertriglyceridemia</cell><cell></cell></row><row><cell>Tipifarnib</cell><cell>Ras, BIM</cell><cell>Phase II</cell><cell>RR Lymphoma</cell><cell>37 DLBCL</cell><cell>ORR: 19%</cell><cell>Not reported</cell><cell>Cytopenias, fatigue (G3</cell><cell>Witzig et al. [113]</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>10%)</cell><cell></cell></row><row><cell>MLN8237</cell><cell>AAK</cell><cell>Phase II</cell><cell>Relapsed</cell><cell>21 DLBCL</cell><cell>ORR: 20%</cell><cell>Not reported</cell><cell>Febrile neutropenia</cell><cell>Friedberg et al.</cell></row><row><cell></cell><cell></cell><cell></cell><cell>aggressive NHL</cell><cell></cell><cell></cell><cell></cell><cell>(15%), diarrhea,</cell><cell>[119]</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>alopecia</cell><cell></cell></row><row><cell cols="9">Abbreviations: ABC, activated B-cell; ALT, alanine aminotransferase; CHOP, rituximab, cyclophosphamide, doxorubicin,</cell></row><row><cell cols="9">vincristine, prednisolone; DA-EPOCH, dose-adjusted etoposide, prednisolone, vincristine, cyclophosphamide, doxorubicin;</cell></row><row><cell cols="9">DLBCL, diffuse large B-cell lymphoma; DLT, dose-limiting toxicity; G, grade; GCB, germinal center B-cell; GEP, gene</cell></row><row><cell cols="9">expression profiling; GI, gastrointestinal; IHC, immunohistochemistry; NHL, non-Hodgkin lymphoma; ORR, overall</cell></row><row><cell cols="9">response rate; OS, overall survival; PFS, progression-free survival; R, rituximab; RCT, randomized controlled trial; RR,</cell></row><row><cell cols="2">relapsed/refractory.</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note></note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">www.TheOncologist.comat MICHIGAN STATE UNIVERSITY LIBRARIES on March 10, 2015 http://theoncologist.alphamedpress.org/ Downloaded from</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="1564">Stratifying DLBCL Treatment by Molecular Hallmarks at MICHIGAN STATE UNIVERSITY LIBRARIES on March 10, 2015 http://theoncologist.alphamedpress.org/ Downloaded from</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="1565">Barton, Hawkes, Wotherspoon et al. www.TheOncologist.com at MICHIGAN STATE UNIVERSITY LIBRARIES on March 10, 2015 http://theoncologist.alphamedpress.org/ Downloaded from</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Stratifying DLBCL Treatment by Molecular Hallmarks at MICHIGAN STATE UNIVERSITY LIBRARIES on March 10, 2015 http://theoncologist.alphamedpress.org/ Downloaded from</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="1567">Barton, Hawkes, Wotherspoon et al. www.TheOncologist.com at MICHIGAN STATE UNIVERSITY LIBRARIES on March 10, 2015 http://theoncologist.alphamedpress.org/ Downloaded from</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="1568">Stratifying DLBCL Treatment by Molecular Hallmarks at MICHIGAN STATE UNIVERSITY LIBRARIES on March 10, 2015 http://theoncologist.alphamedpress.org/ Downloaded from</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="1569">Barton, Hawkes, Wotherspoon et al. www.TheOncologist.com at MICHIGAN STATE UNIVERSITY LIBRARIES on March 10, 2015 http://theoncologist.alphamedpress.org/ Downloaded from</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="1570">Stratifying DLBCL Treatment by Molecular Hallmarks at MICHIGAN STATE UNIVERSITY LIBRARIES on March 10, 2015 http://theoncologist.alphamedpress.org/ Downloaded from</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Barton, Hawkes, Wotherspoon et al. www.TheOncologist.com at MICHIGAN STATE UNIVERSITY LIBRARIES on March 10, 2015 http://theoncologist.alphamedpress.org/ Downloaded from</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">This article has been cited by 1 HighWire-hosted articles:at MICHIGAN STATE UNIVERSITY LIBRARIES on March 10, 2015 http://theoncologist.alphamedpress.org/ Downloaded from</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">at MICHIGAN STATE UNIVERSITY LIBRARIES on March 10, 2015 http://theoncologist.alphamedpress.org/ Downloaded from</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ACKNOWLEDGMENTS</head><p>This work was supported by National Health Service funding to the National Institute for Health Research Biomedical Research Centre.</p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>AUTHOR CONTRIBUTIONS</head><p>The online version of this article, along with updated information and services, is</p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">The Haematological Malignancy Research Network (HMRN): A new information strategy for population based epidemiology and health service research</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Roman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Howell</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Haematol</title>
		<imprint>
			<biblScope unit="volume">148</biblScope>
			<biblScope unit="page" from="739" to="753" />
			<date type="published" when="2010" />
		</imprint>
	</monogr>
	<note type="raw_reference">Smith A, Roman E, Howell D et al. The Haemato- logical Malignancy Research Network (HMRN): A new information strategy for population based epidemiology and health service research. Br J Haematol 2010;148: 739 -753.</note>
</biblStruct>

<biblStruct xml:id="b1">
	<monogr>
		<title level="m" type="main">WHO classification of tumours of haematopoietic and lymphoid tissues</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">H</forename><surname>Swerdlow</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Campo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><forename type="middle">L</forename><surname>Harris</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2008" />
			<publisher>World Health Organization</publisher>
			<pubPlace>Lyons, France</pubPlace>
		</imprint>
	</monogr>
	<note type="raw_reference">Swerdlow SH, Campo E, Harris NL. WHO classifi- cation of tumours of haematopoietic and lymphoid tis- sues. Lyons, France: World Health Organization, 2008.</note>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Coiffier</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Lepage</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Briere</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">346</biblScope>
			<biblScope unit="page" from="235" to="242" />
			<date type="published" when="2002" />
		</imprint>
	</monogr>
	<note type="raw_reference">Coiffier B, Lepage E, Briere J et al. CHOP chemo- therapy plus rituximab compared with CHOP alone in el- derly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-242.</note>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">CHOP-like chemotherapy plus rituximab versus CHOPlike chemotherapy alone in young patients with goodprognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Pfreundschuh</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Trumper</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Osterborg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="379" to="391" />
			<date type="published" when="2006" />
		</imprint>
	</monogr>
	<note type="raw_reference">Pfreundschuh M, Trumper L, Osterborg A et al. CHOP-like chemotherapy plus rituximab versus CHOP- like chemotherapy alone in young patients with good- prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379 -391.</note>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20ϩ B-cell lymphomas: A randomised controlled trial (RICOVER-60)</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Pfreundschuh</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Schubert</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Ziepert</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="105" to="116" />
			<date type="published" when="2008" />
		</imprint>
	</monogr>
	<note type="raw_reference">Pfreundschuh M, Schubert J, Ziepert M et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggres- sive CD20ϩ B-cell lymphomas: A randomised con- trolled trial (RICOVER-60). Lancet Oncol 2008;9: 105-116.</note>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">CHOPlike chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Pfreundschuh</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Kuhnt</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Trumper</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Trial (MInT) Group. Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="1013" to="1022" />
			<date type="published" when="2011" />
		</imprint>
	</monogr>
	<note type="raw_reference">Pfreundschuh M, Kuhnt E, Trumper L et al. CHOP- like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lym- phoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lan- cet Oncol 2011;12:1013-1022.</note>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Diffuse large B-cell non-Hodgkin&apos;s lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Tilly</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Dreyling</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Oncol</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="110" to="112" />
			<date type="published" when="2009" />
		</imprint>
	</monogr>
	<note>suppl</note>
	<note type="raw_reference">Tilly H, Dreyling M. Diffuse large B-cell non-Hodg- kin&apos;s lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20(suppl 4):110 -112.</note>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Ten-year relative survival and causes of death in elderly patients treated with R-CHOP or CHOP in the GELA LNH-985 trial</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Mounier</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Heutte</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Thieblemont</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Lymphoma Myeloma Leuk</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="151" to="154" />
			<date type="published" when="2012" />
		</imprint>
	</monogr>
	<note type="raw_reference">Mounier N, Heutte N, Thieblemont C et al. Ten-year relative survival and causes of death in elderly patients treated with R-CHOP or CHOP in the GELA LNH-985 trial. Clin Lymphoma Myeloma Leuk 2012;12:151-154.</note>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">M</forename><surname>Habermann</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><forename type="middle">A</forename><surname>Weller</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><forename type="middle">A</forename><surname>Morrison</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="3121" to="3127" />
			<date type="published" when="2006" />
		</imprint>
	</monogr>
	<note type="raw_reference">Habermann TM, Weller EA, Morrison VA et al. Rituximab-CHOP versus CHOP alone or with main- tenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006;24:3121-3127.</note>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">H</forename><surname>Sehn</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Donaldson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Chhanabhai</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="5027" to="5033" />
			<date type="published" when="2005" />
		</imprint>
	</monogr>
	<note type="raw_reference">Sehn LH, Donaldson J, Chhanabhai M et al. Intro- duction of combined CHOP plus rituximab therapy dra- matically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005;23: 5027-5033.</note>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20ϩ B-cell lymphoma in the rituximab era</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Ziepert</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Hasenclever</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Kuhnt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="2373" to="2380" />
			<date type="published" when="2011" />
		</imprint>
	</monogr>
	<note type="raw_reference">Ziepert M, Hasenclever D, Kuhnt E et al. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20ϩ B-cell lymphoma in the rituximab era. J Clin Oncol 2011;28: 2373-2380.</note>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Paik</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Shak</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Tang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">351</biblScope>
			<biblScope unit="page" from="2817" to="2826" />
			<date type="published" when="2004" />
		</imprint>
	</monogr>
	<note type="raw_reference">Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817-2826.</note>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">A</forename><surname>Alizadeh</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">B</forename><surname>Eisen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">E</forename><surname>Davis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">403</biblScope>
			<biblScope unit="page" from="503" to="511" />
			<date type="published" when="2000" />
		</imprint>
	</monogr>
	<note type="raw_reference">Alizadeh AA, Eisen MB, Davis RE et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503- 511.</note>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Rosenwald</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Wright</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">C</forename><surname>Chan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">346</biblScope>
			<biblScope unit="page" from="1937" to="1947" />
			<date type="published" when="2002" />
		</imprint>
	</monogr>
	<note type="raw_reference">Rosenwald A, Wright G, Chan WC et al. The use of molecular profiling to predict survival after chemother- apy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346:1937-1947.</note>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Wright</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Tan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Rosenwald</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci U S A</title>
		<imprint>
			<biblScope unit="volume">100</biblScope>
			<biblScope unit="page" from="9991" to="9996" />
			<date type="published" when="2003" />
		</imprint>
	</monogr>
	<note type="raw_reference">Wright G, Tan B, Rosenwald A et al. A gene ex- pression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A 2003;100:9991-9996.</note>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">A</forename><surname>Shipp</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">N</forename><surname>Ross</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Tamayo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Med</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="68" to="74" />
			<date type="published" when="2002" />
		</imprint>
	</monogr>
	<note type="raw_reference">Shipp MA, Ross KN, Tamayo P et al. Diffuse large B-cell lymphoma outcome prediction by gene-expres- sion profiling and supervised machine learning. Nat Med 2002;8:68 -74.</note>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Monti</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">J</forename><surname>Savage</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">L</forename><surname>Kutok</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">105</biblScope>
			<biblScope unit="page" from="1851" to="1861" />
			<date type="published" when="2005" />
		</imprint>
	</monogr>
	<note type="raw_reference">Monti S, Savage KJ, Kutok JL et al. Molecular pro- filing of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflamma- tory response. Blood 2005;105:1851-1861.</note>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Analysis of the coding genome of diffuse large B-cell lymphoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Pasqualucci</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><surname>Trifonov</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Fabbri</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Genet</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="page" from="830" to="837" />
			<date type="published" when="2011" />
		</imprint>
	</monogr>
	<note type="raw_reference">Pasqualucci L, Trifonov V, Fabbri G et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet 2011;43:830 -837.</note>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Inactivating mutations of acetyltransferase genes in B-cell lymphoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Pasqualucci</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Dominguez-Sola</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Chiarenza</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">471</biblScope>
			<biblScope unit="page" from="189" to="195" />
			<date type="published" when="2011" />
		</imprint>
	</monogr>
	<note type="raw_reference">Pasqualucci L, Dominguez-Sola D, Chiarenza A et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 2011;471:189 -195.</note>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">G</forename><surname>Lohr</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Stojanov</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">S</forename><surname>Lawrence</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci U S A</title>
		<imprint>
			<biblScope unit="volume">109</biblScope>
			<biblScope unit="page" from="3879" to="3884" />
			<date type="published" when="2012" />
		</imprint>
	</monogr>
	<note type="raw_reference">Lohr JG, Stojanov P, Lawrence MS et al. Discov- ery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome se- quencing. Proc Natl Acad Sci U S A 2012;109:3879 - 3884.</note>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">D</forename><surname>Morin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Mendez-Lago</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">J</forename><surname>Mungall</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">476</biblScope>
			<biblScope unit="page" from="298" to="303" />
			<date type="published" when="2011" />
		</imprint>
	</monogr>
	<note type="raw_reference">Morin RD, Mendez-Lago M, Mungall AJ et al. Fre- quent mutation of histone-modifying genes in non- Hodgkin lymphoma. Nature 2011;476:298 -303.</note>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Stromal gene signatures in large-B-cell lymphomas</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Lenz</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Wright</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">S</forename><surname>Dave</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">359</biblScope>
			<biblScope unit="page" from="2313" to="2323" />
			<date type="published" when="2008" />
		</imprint>
	</monogr>
	<note type="raw_reference">Lenz G, Wright G, Dave SS et al. Stromal gene sig- natures in large-B-cell lymphomas. N Engl J Med 2008; 359:2313-2323.</note>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Protein kinase C beta controls nuclear factor kappaB activation in B cells through selective regulation of the IkappaB kinase alpha</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Saijo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><surname>Mecklenbrauker</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Santana</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Exp Med</title>
		<imprint>
			<biblScope unit="volume">195</biblScope>
			<biblScope unit="page" from="1647" to="1652" />
			<date type="published" when="2002" />
		</imprint>
	</monogr>
	<note type="raw_reference">Saijo K, Mecklenbrauker I, Santana A et al. Protein kinase C beta controls nuclear factor kappaB activation in B cells through selective regulation of the IkappaB ki- nase alpha. J Exp Med 2002;195:1647-1652.</note>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">P</forename><surname>Jais</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Haioun</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">J</forename><surname>Molina</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="1917" to="1924" />
			<date type="published" when="2008" />
		</imprint>
	</monogr>
	<note type="raw_reference">Jais JP, Haioun C, Molina TJ et al. The expression of 16 genes related to the cell of origin and immune re- sponse predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and ritux- imab. Leukemia 2008;22:1917-1924.</note>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Gutierrez-Garcia</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Cardesa-Salzmann</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Climent</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">117</biblScope>
			<biblScope unit="page" from="4836" to="4843" />
			<date type="published" when="2011" />
		</imprint>
	</monogr>
	<note type="raw_reference">Gutierrez-Garcia G, Cardesa-Salzmann T, Climent F et al. Gene-expression profiling and not immunophe- notypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunoche- motherapy. Blood 2011;117:4836 -4843.</note>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">A new immunostain algorithm classifies diffuse large Bcell lymphoma into molecular subtypes with high accuracy</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">W</forename><surname>Choi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">D</forename><surname>Weisenburger</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">C</forename><surname>Greiner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="5494" to="5502" />
			<date type="published" when="2009" />
		</imprint>
	</monogr>
	<note type="raw_reference">Choi WW, Weisenburger DD, Greiner TC et al. A new immunostain algorithm classifies diffuse large B- cell lymphoma into molecular subtypes with high accu- racy. Clin Cancer Res 2009;15:5494 -5502.</note>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">M</forename><surname>Rimsza</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">L</forename><surname>Leblanc</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">M</forename><surname>Unger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">112</biblScope>
			<biblScope unit="page" from="3425" to="3433" />
			<date type="published" when="2008" />
		</imprint>
	</monogr>
	<note type="raw_reference">Rimsza LM, Leblanc ML, Unger JM et al. Gene ex- pression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R- CHOP. Blood 2008;112:3425-3433.</note>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Accurate classification of diffuse large B-cell lymphoma into germinal center and activated B-cell subtypes using a nuclease protection assay on formalin-fixed, paraffinembedded tissues</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">M</forename><surname>Rimsza</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Wright</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Schwartz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="3727" to="3732" />
			<date type="published" when="2011" />
		</imprint>
	</monogr>
	<note type="raw_reference">Rimsza LM, Wright G, Schwartz M et al. Accurate classification of diffuse large B-cell lymphoma into ger- minal center and activated B-cell subtypes using a nu- clease protection assay on formalin-fixed, paraffin- embedded tissues. Clin Cancer Res 2011;17:3727-3732.</note>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Microarray gene expression analysis of fixed archival tissue permits molecular classification and identification of potential therapeutic targets in diffuse large B-cell lymphoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Linton</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Howarth</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Wappett</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Mol Diagn</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="223" to="232" />
			<date type="published" when="2012" />
		</imprint>
	</monogr>
	<note type="raw_reference">Linton K, Howarth C, Wappett M et al. Microarray gene expression analysis of fixed archival tissue permits molecular classification and identification of potential therapeutic targets in diffuse large B-cell lymphoma. J Mol Diagn 2012;14:223-232.</note>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">P</forename><surname>Hans</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">D</forename><surname>Weisenburger</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">C</forename><surname>Greiner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">103</biblScope>
			<biblScope unit="page" from="275" to="282" />
			<date type="published" when="2004" />
		</imprint>
	</monogr>
	<note type="raw_reference">Hans CP, Weisenburger DD, Greiner TC et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275-282.</note>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">N</forename><surname>Meyer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Fu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">C</forename><surname>Greiner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="200" to="207" />
			<date type="published" when="2011" />
		</imprint>
	</monogr>
	<note type="raw_reference">Meyer PN, Fu K, Greiner TC et al. Immunohisto- chemical methods for predicting cell of origin and sur- vival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol 2011;29:200 -207.</note>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">The Hans classificator does not predict outcome in diffuse large B cell lymphoma in a large multicenter retrospective analysis of R-CHOP treated patients</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><forename type="middle">T</forename><surname>Hill</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Amb</forename><surname>Collie</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Radivoyevitch</surname></persName>
		</author>
		<idno>Abstract 950. 33</idno>
	</analytic>
	<monogr>
		<title level="j">Leuk Res</title>
		<imprint>
			<biblScope unit="volume">118</biblScope>
			<biblScope unit="page" from="544" to="545" />
			<date type="published" when="2011" />
		</imprint>
	</monogr>
	<note>Blood</note>
	<note type="raw_reference">Hill BT, Collie AMB, Radivoyevitch T, et al. Cell of origin determination in diffuse large b-cell lympho- ma: Performance of immunohistochemical (IHC) algo- rithms and ability to predict outcome. Blood 2011; 118(suppl 21):Abstract 950. 33. Ott MM, Horn H, Kaufmann M et al. The Hans classificator does not predict outcome in diffuse large B cell lymphoma in a large multicenter retrospective anal- ysis of R-CHOP treated patients. Leuk Res 2012;36: 544 -545.</note>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">E</forename><surname>Davis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">D</forename><surname>Brown</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">U</forename><surname>Siebenlist</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Exp Med</title>
		<imprint>
			<biblScope unit="volume">194</biblScope>
			<biblScope unit="page" from="1861" to="1874" />
			<date type="published" when="2001" />
		</imprint>
	</monogr>
	<note type="raw_reference">Davis RE, Brown KD, Siebenlist U et al. Constitu- tive nuclear factor kappaB activity is required for sur- vival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2001;194:1861-1874.</note>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">T</forename><surname>Lam</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Wright</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">E</forename><surname>Davis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">111</biblScope>
			<biblScope unit="page" from="3701" to="3713" />
			<date type="published" when="2008" />
		</imprint>
	</monogr>
	<note type="raw_reference">Lam LT, Wright G, Davis RE et al. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma. Blood 2008; 111:3701-3713.</note>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">A loss-of-function RNA interference screen for molecular targets in cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><forename type="middle">N</forename><surname>Ngo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">E</forename><surname>Davis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Lamy</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">441</biblScope>
			<biblScope unit="page" from="106" to="110" />
			<date type="published" when="2006" />
		</imprint>
	</monogr>
	<note type="raw_reference">Ngo VN, Davis RE, Lamy L et al. A loss-of-func- tion RNA interference screen for molecular targets in cancer. Nature 2006;441:106 -110.</note>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">T</forename><surname>Lam</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">E</forename><surname>Davis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Pierce</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="28" to="40" />
			<date type="published" when="2005" />
		</imprint>
	</monogr>
	<note type="raw_reference">Lam LT, Davis RE, Pierce J et al. Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. Clin Cancer Res 2005;11:28 - 40.</note>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Compagno</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">K</forename><surname>Lim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Grunn</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">459</biblScope>
			<biblScope unit="page" from="717" to="721" />
			<date type="published" when="2009" />
		</imprint>
	</monogr>
	<note type="raw_reference">Compagno M, Lim WK, Grunn A et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 2009;459:717- 721.</note>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Pathogenesis of non-Hodgkin&apos;s lymphoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Nogai</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Dorken</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Lenz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="1803" to="1811" />
			<date type="published" when="2011" />
		</imprint>
	</monogr>
	<note type="raw_reference">Nogai H, Dorken B, Lenz G. Pathogenesis of non- Hodgkin&apos;s lymphoma. J Clin Oncol 2011;29:1803- 1811.</note>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">E</forename><surname>Davis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><forename type="middle">N</forename><surname>Ngo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Lenz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">463</biblScope>
			<biblScope unit="page" from="88" to="92" />
			<date type="published" when="2010" />
		</imprint>
	</monogr>
	<note type="raw_reference">Davis RE, Ngo VN, Lenz G et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lym- phoma. Nature 2010;463:88 -92.</note>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Survival of resting mature B lymphocytes depends on BCR signaling via the Igalpha/beta heterodimer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Kraus</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">B</forename><surname>Alimzhanov</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Rajewsky</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell</title>
		<imprint>
			<biblScope unit="volume">117</biblScope>
			<biblScope unit="page" from="787" to="800" />
			<date type="published" when="2004" />
		</imprint>
	</monogr>
	<note type="raw_reference">Kraus M, Alimzhanov MB, Rajewsky N et al. Sur- vival of resting mature B lymphocytes depends on BCR signaling via the Igalpha/beta heterodimer. Cell 2004; 117:787-800.</note>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Frequent inactivation of A20 in B-cell lymphomas</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Kato</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Sanada</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><surname>Kato</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">459</biblScope>
			<biblScope unit="page" from="712" to="716" />
			<date type="published" when="2009" />
		</imprint>
	</monogr>
	<note type="raw_reference">Kato M, Sanada M, Kato I et al. Frequent inactiva- tion of A20 in B-cell lymphomas. Nature 2009;459:712- 716.</note>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Lenz</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><forename type="middle">W</forename><surname>Wright</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><forename type="middle">C</forename><surname>Emre</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci U S A</title>
		<imprint>
			<biblScope unit="volume">105</biblScope>
			<biblScope unit="page" from="13520" to="13525" />
			<date type="published" when="2008" />
		</imprint>
	</monogr>
	<note type="raw_reference">Lenz G, Wright GW, Emre NC et al. Molecular subtypes of diffuse large B-cell lymphoma arise by dis- tinct genetic pathways. Proc Natl Acad Sci U S A 2008; 105:13520 -13525.</note>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Pasqualucci</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Compagno</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Houldsworth</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Exp Med</title>
		<imprint>
			<biblScope unit="volume">203</biblScope>
			<biblScope unit="page" from="311" to="317" />
			<date type="published" when="2006" />
		</imprint>
	</monogr>
	<note type="raw_reference">Pasqualucci L, Compagno M, Houldsworth J et al. Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma. J Exp Med 2006;203:311-317.</note>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Mandelbaum</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Bhagat</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Tang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">PIM inhibition as a rational therapeutic approach in dif</title>
		<imprint>
			<date type="published" when="2010" />
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="568" to="579" />
		</imprint>
	</monogr>
	<note type="raw_reference">Mandelbaum J, Bhagat G, Tang H et al. BLIMP1 is a tumor suppressor gene frequently disrupted in acti- vated B cell-like diffuse large B cell lymphoma. Cancer Cell 2010;18:568 -579. 46. Gomez-Abad C, Pisonero H, Blanco-Aparicio C. PIM inhibition as a rational therapeutic approach in dif-</note>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">D</forename><surname>Morin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><forename type="middle">A</forename><surname>Johnson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">M</forename><surname>Severson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Genet</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="181" to="185" />
			<date type="published" when="2010" />
		</imprint>
	</monogr>
	<note type="raw_reference">Morin RD, Johnson NA, Severson TM et al. So- matic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 2010;42:181-185.</note>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">TP53 mutations predict for poor survival in de novo diffuse large B-cell lymphoma of germinal center subtype</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">J</forename><surname>Ryan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Nitta</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Borger</surname></persName>
		</author>
		<idno>e28585. 64</idno>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="60" to="66" />
			<date type="published" when="2009" />
		</imprint>
	</monogr>
	<note>Leuk Res</note>
	<note type="raw_reference">Ryan RJ, Nitta M, Borger D et al. EZH2 codon 641 mutations are common in BCL2-rearranged germinal center B cell lymphomas. PLoS One 2011;6:e28585. 64. Zainuddin N, Berglund M, Wanders A et al. TP53 mutations predict for poor survival in de novo diffuse large B-cell lymphoma of germinal center subtype. Leuk Res 2009;33:60 -66.</note>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">H</forename><surname>Young</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">D</forename><surname>Weisenburger</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Dave</forename><surname>Bj</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">110</biblScope>
			<biblScope unit="page" from="4396" to="4405" />
			<date type="published" when="2007" />
		</imprint>
	</monogr>
	<note type="raw_reference">Young KH, Weisenburger DD, Dave BJ et al. Mu- tations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILrecep- tor-2, predict for poor survival in diffuse large B-cell lymphoma. Blood 2007;110:4396 -4405.</note>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Combined genetic inactivation of beta2-microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">H</forename><surname>Young</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Leroy</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">B</forename><surname>Moller</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Cell</title>
		<imprint>
			<biblScope unit="volume">112</biblScope>
			<biblScope unit="page" from="728" to="740" />
			<date type="published" when="2008" />
		</imprint>
	</monogr>
	<note>Blood</note>
	<note type="raw_reference">Young KH, Leroy K, Moller MB et al. Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international col- laborative study. Blood 2008;112:3088 -3098. 67. Challa-Malladi M, Lieu YK, Califano O et al. Combined genetic inactivation of beta2-microglobulin and CD58 reveals frequent escape from immune recog- nition in diffuse large B cell lymphoma. Cancer Cell 2011;20:728 -740.</note>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: A GELA study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Copie-Bergman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Gaulard</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Leroy</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="5573" to="5579" />
			<date type="published" when="2009" />
		</imprint>
	</monogr>
	<note type="raw_reference">Copie-Bergman C, Gaulard P, Leroy K et al. Im- muno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: A GELA study. J Clin Oncol 2009;27:5573-5579.</note>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Role of phosphatidylinositol 3Ј-kinase/AKT pathway in diffuse large B-cell lymphoma survival</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Uddin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">R</forename><surname>Hussain</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">K</forename><surname>Siraj</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">108</biblScope>
			<biblScope unit="page" from="4178" to="4186" />
			<date type="published" when="2006" />
		</imprint>
	</monogr>
	<note type="raw_reference">Uddin S, Hussain AR, Siraj AK et al. Role of phos- phatidylinositol 3Ј-kinase/AKT pathway in diffuse large B-cell lymphoma survival. Blood 2006;108:4178 - 4186.</note>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">R-CHOP14 versus R-CHOP21: Result of a randomized phase III trial for the treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Cunningham</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Mouncey</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page">8000</biblScope>
			<date type="published" when="2011" />
		</imprint>
	</monogr>
	<note>suppl</note>
	<note type="raw_reference">Cunningham D, Smith P, Mouncey P, et al. R- CHOP14 versus R-CHOP21: Result of a randomized phase III trial for the treatment of patients with newly di- agnosed diffuse large B-cell non-Hodgkin lymphoma. J Clin Oncol 2011;29(15 suppl):8000.</note>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">A systematic review and meta-analysis of rituximab-based immunochemotherapy for subtypes of diffuse large B cell lymphoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Fang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">Y</forename><surname>Li</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Hematol</title>
		<imprint>
			<biblScope unit="volume">89</biblScope>
			<biblScope unit="page" from="1107" to="1113" />
			<date type="published" when="2010" />
		</imprint>
	</monogr>
	<note type="raw_reference">Fang C, Xu W, Li JY. A systematic review and meta-analysis of rituximab-based immunochemo- therapy for subtypes of diffuse large B cell lymphoma. Ann Hematol 2010;89:1107-1113.</note>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin&apos;s lymphoma B-cell lines: Role in sensitization to chemotherapeutic drug-induced apoptosis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">R</forename><surname>Jazirehi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Huerta-Yepez</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Cheng</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="page" from="264" to="276" />
			<date type="published" when="2005" />
		</imprint>
	</monogr>
	<note type="raw_reference">Jazirehi AR, Huerta-Yepez S, Cheng G et al. Ritux- imab (chimeric anti-CD20 monoclonal antibody) inhib- its the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin&apos;s lymphoma B-cell lines: Role in sensitization to chemotherapeutic drug-induced apo- ptosis. Cancer Res 2005;65:264 -276.</note>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: Validation of tissue microarray as a prerequisite for broad clinical applications (a study from the Lunenburg Lymphoma Biomarker Consortium)</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>De Jong</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><surname>Xie</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Rosenwald</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Pathol</title>
		<imprint>
			<biblScope unit="volume">62</biblScope>
			<biblScope unit="page" from="128" to="138" />
			<date type="published" when="2009" />
		</imprint>
	</monogr>
	<note type="raw_reference">de Jong D, Xie W, Rosenwald A et al. Immunohis- tochemical prognostic markers in diffuse large B-cell lymphoma: Validation of tissue microarray as a prereq- uisite for broad clinical applications (a study from the Lunenburg Lymphoma Biomarker Consortium). J Clin Pathol 2009;62:128 -138.</note>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Nyman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Adde</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">L</forename><surname>Karjalainen-Lindsberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">109</biblScope>
			<biblScope unit="page" from="4930" to="4935" />
			<date type="published" when="2007" />
		</imprint>
	</monogr>
	<note type="raw_reference">Nyman H, Adde M, Karjalainen-Lindsberg ML et al. Prognostic impact of immunohistochemically de- fined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood 2007;109:4930 -4935.</note>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main">Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and nongerminal center B-cell-like subtypes of diffuse large B-cell lymphoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Fu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">D</forename><surname>Weisenburger</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">W</forename><surname>Choi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="4587" to="4594" />
			<date type="published" when="2008" />
		</imprint>
	</monogr>
	<note type="raw_reference">Fu K, Weisenburger DD, Choi WW et al. Addition of rituximab to standard chemotherapy improves the sur- vival of both the germinal center B-cell-like and non- germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. J Clin Oncol 2008;26:4587-4594.</note>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main">Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Dunleavy</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Pittaluga</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">S</forename><surname>Czuczman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">113</biblScope>
			<biblScope unit="page" from="6069" to="6076" />
			<date type="published" when="2009" />
		</imprint>
	</monogr>
	<note type="raw_reference">Dunleavy K, Pittaluga S, Czuczman MS et al. Dif- ferential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lym- phoma. Blood 2009;113:6069 -6076.</note>
</biblStruct>

<biblStruct xml:id="b57">
	<analytic>
		<title level="a" type="main">A cancer and leukemia group B multi-center study of DA-EPOCHrituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><surname>Wilson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">H</forename><surname>Jung</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Porcu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Haematologica</title>
		<imprint>
			<biblScope unit="volume">97</biblScope>
			<biblScope unit="page" from="758" to="765" />
			<date type="published" when="2012" />
		</imprint>
	</monogr>
	<note type="raw_reference">Wilson W, Jung SH, Porcu P et al. A cancer and leukemia group B multi-center study of DA-EPOCH- rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. Haema- tologica 2012;97:758 -765.</note>
</biblStruct>

<biblStruct xml:id="b58">
	<analytic>
		<title level="a" type="main">Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">H</forename><surname>Wilson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Dunleavy</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Pittaluga</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="2717" to="2724" />
			<date type="published" when="2008" />
		</imprint>
	</monogr>
	<note type="raw_reference">Wilson WH, Dunleavy K, Pittaluga S et al. Phase II study of dose-adjusted EPOCH and rituximab in un- treated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol 2008;26:2717-2724.</note>
</biblStruct>

<biblStruct xml:id="b59">
	<analytic>
		<title level="a" type="main">Development of the proteasome inhibitor Velcade (Bortezomib)</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Adams</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Kauffman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Invest</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="304" to="311" />
			<date type="published" when="2004" />
		</imprint>
	</monogr>
	<note type="raw_reference">Adams J, Kauffman M. Development of the pro- teasome inhibitor Velcade (Bortezomib). Cancer Invest 2004;22:304 -311.</note>
</biblStruct>

<biblStruct xml:id="b60">
	<analytic>
		<title level="a" type="main">Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Ruan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Martin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">R</forename><surname>Furman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="690" to="697" />
			<date type="published" when="2011" />
		</imprint>
	</monogr>
	<note type="raw_reference">Ruan J, Martin P, Furman RR et al. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J Clin Oncol 2011;29:690 -697.</note>
</biblStruct>

<biblStruct xml:id="b61">
	<analytic>
		<title level="a" type="main">A phase I/II study of bortezomib plus CHOP every 2 weeks (CHOP-14) in patients with advanced-stage diffuse large B-cell lymphomas</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">E</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">H</forename><surname>Yoon</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Jang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Korean J Hematol</title>
		<imprint>
			<biblScope unit="volume">47</biblScope>
			<biblScope unit="page" from="53" to="59" />
			<date type="published" when="2012" />
		</imprint>
	</monogr>
	<note type="raw_reference">Kim JE, Yoon DH, Jang G et al. A phase I/II study of bortezomib plus CHOP every 2 weeks (CHOP-14) in patients with advanced-stage diffuse large B-cell lym- phomas. Korean J Hematol 2012;47:53-59.</note>
</biblStruct>

<biblStruct xml:id="b62">
	<analytic>
		<title level="a" type="main">An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin&apos;s lymphoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">E</forename><surname>Witzig</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">M</forename><surname>Vose</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">L</forename><surname>Zinzani</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Oncol</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="1622" to="1627" />
			<date type="published" when="2011" />
		</imprint>
	</monogr>
	<note type="raw_reference">Witzig TE, Vose JM, Zinzani PL et al. An interna- tional phase II trial of single-agent lenalidomide for re- lapsed or refractory aggressive B-cell non-Hodgkin&apos;s lymphoma. Ann Oncol 2011;22:1622-1627.</note>
</biblStruct>

<biblStruct xml:id="b63">
	<analytic>
		<title level="a" type="main">Combination of lenalidomide with R-CHOP (R2CHOP) as an initial therapy for aggressive B-cell lymphomas: A phase I/II study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">H</forename><surname>Wiernik</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><forename type="middle">S</forename><surname>Lossos</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">M</forename><surname>Tuscano</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page">8015</biblScope>
			<date type="published" when="2008" />
		</imprint>
	</monogr>
	<note>J Clin Oncol. suppl</note>
	<note type="raw_reference">Wiernik PH, Lossos IS, Tuscano JM et al. Lena- lidomide monotherapy in relapsed or refractory aggres- sive non-Hodgkin&apos;s lymphoma. J Clin Oncol 2008;26: 4952-4957. 84. Nowakowski GS, Reeder CB, LaPlant B et al. Combination of lenalidomide with R-CHOP (R2CHOP) as an initial therapy for aggressive B-cell lymphomas: A phase I/II study. J Clin Oncol 2011;29(15 suppl):8015.</note>
</biblStruct>

<biblStruct xml:id="b64">
	<analytic>
		<title level="a" type="main">Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">A</forename><surname>Keifer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">C</forename><surname>Guttridge</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><forename type="middle">P</forename><surname>Ashburner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Biol Chem</title>
		<imprint>
			<biblScope unit="volume">276</biblScope>
			<biblScope unit="page" from="22382" to="22387" />
			<date type="published" when="2001" />
		</imprint>
	</monogr>
	<note type="raw_reference">Keifer JA, Guttridge DC, Ashburner BP et al. In- hibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J Biol Chem 2001;276:22382-22387.</note>
</biblStruct>

<biblStruct xml:id="b65">
	<analytic>
		<title level="a" type="main">Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">L</forename><surname>Shaffer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><forename type="middle">C</forename><surname>Emre</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Cell</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="723" to="737" />
		</imprint>
	</monogr>
	<note type="raw_reference">Yang Y, Shaffer AL 3rd, Emre NC et al. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell;21:723-737.</note>
</biblStruct>

<biblStruct xml:id="b66">
	<analytic>
		<title level="a" type="main">Higher response to lenalidomide in relapsed/refractory diffuse large b-cell lymphoma in nongerminal center Bcell-like than in germinal center B-cell-like phenotype</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><forename type="middle">J</forename><surname>Hernandez-Ilizaliturri</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Deeb</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">L</forename><surname>Zinzani</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer</title>
		<imprint>
			<biblScope unit="volume">117</biblScope>
			<biblScope unit="page" from="5058" to="5066" />
			<date type="published" when="2011" />
		</imprint>
	</monogr>
	<note type="raw_reference">Hernandez-Ilizaliturri FJ, Deeb G, Zinzani PL et al. Higher response to lenalidomide in relapsed/refractory diffuse large b-cell lymphoma in nongerminal center B- cell-like than in germinal center B-cell-like phenotype. Cancer 2011;117:5058 -5066.</note>
</biblStruct>

<biblStruct xml:id="b67">
	<analytic>
		<title level="a" type="main">SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Monti</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Juszczynski</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">111</biblScope>
			<biblScope unit="page" from="2230" to="2237" />
			<date type="published" when="2008" />
		</imprint>
	</monogr>
	<note type="raw_reference">Chen L, Monti S, Juszczynski P et al. SYK-depen- dent tonic B-cell receptor signaling is a rational treat- ment target in diffuse large B-cell lymphoma. Blood 2008;111:2230 -2237.</note>
</biblStruct>

<biblStruct xml:id="b68">
	<analytic>
		<title level="a" type="main">Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">W</forename><surname>Friedberg</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Sharman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Sweetenham</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">115</biblScope>
			<biblScope unit="page" from="2578" to="2585" />
			<date type="published" when="2010" />
		</imprint>
	</monogr>
	<note type="raw_reference">Friedberg JW, Sharman J, Sweetenham J et al. In- hibition of Syk with fostamatinib disodium has signifi- cant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010;115:2578 - 2585.</note>
</biblStruct>

<biblStruct xml:id="b69">
	<analytic>
		<title level="a" type="main">The Bruton tyrosine kinase inhibitor PCI-32765 blocks Bcell activation and is efficacious in models of autoimmune disease and B-cell malignancy</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">A</forename><surname>Honigberg</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">M</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Sirisawad</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci U S A</title>
		<imprint>
			<biblScope unit="volume">107</biblScope>
			<biblScope unit="page" from="13075" to="13080" />
			<date type="published" when="2010" />
		</imprint>
	</monogr>
	<note type="raw_reference">Honigberg LA, Smith AM, Sirisawad M et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B- cell activation and is efficacious in models of autoim- mune disease and B-cell malignancy. Proc Natl Acad Sci U S A 2010;107:13075-13080.</note>
</biblStruct>

<biblStruct xml:id="b70">
	<analytic>
		<title level="a" type="main">The Bruton&apos;s tyrosine kinase (BTK) inhibitor PCI-32765 inhibits growth of ABC DLBCL tumors in vivo and in vitro by preventing activation of pro-survival NF-{kappa}B pathways</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Balasubramanian</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Crowley</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Sirisawad</surname></persName>
		</author>
		<idno>4969. 92</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Oncol</title>
		<imprint>
			<biblScope unit="volume">118</biblScope>
			<date type="published" when="2011" />
		</imprint>
	</monogr>
	<note>Blood. suppl 4):Abstract 153</note>
	<note type="raw_reference">Balasubramanian S, Crowley R, Sirisawad M et al. The Bruton&apos;s tyrosine kinase (BTK) inhibitor PCI- 32765 inhibits growth of ABC DLBCL tumors in vivo and in vitro by preventing activation of pro-survival NF- {kappa}B pathways. Blood 2011;118:Abstract 4969. 92. Advani R, Shamman J, Smith S. The BTK Inihibi- tor PCI-32765 is highly active and well tolerated in pa- tients with relapsed/refractory B cell malignancies: Final results from a phase I study. Ann Oncol 2011;22(suppl 4):Abstract 153.</note>
</biblStruct>

<biblStruct xml:id="b71">
	<analytic>
		<title level="a" type="main">The Bruton&apos;s tyrosine kinase (Btk) inhibitor PCI-32765 modulates chronic active BCR Signaling and induces tumor regression in relapsed/refractory ABC DLBCL</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">M</forename><surname>Staudt</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Dunleavy</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">J</forename><surname>Buggy</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">118</biblScope>
			<date type="published" when="2011" />
		</imprint>
	</monogr>
	<note type="raw_reference">Staudt LM, Dunleavy K, Buggy JJ et al. The Bru- ton&apos;s tyrosine kinase (Btk) inhibitor PCI-32765 modu- lates chronic active BCR Signaling and induces tumor regression in relapsed/refractory ABC DLBCL. Blood 2011;118:Abstract 2716.</note>
</biblStruct>

<biblStruct xml:id="b72">
	<analytic>
		<title level="a" type="main">The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">O</forename><surname>Hantschel</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">U</forename><surname>Rix</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">U</forename><surname>Schmidt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci U S A</title>
		<imprint>
			<biblScope unit="volume">104</biblScope>
			<biblScope unit="page" from="13283" to="13288" />
			<date type="published" when="2007" />
		</imprint>
	</monogr>
	<note type="raw_reference">Hantschel O, Rix U, Schmidt U et al. The Btk ty- rosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci U S A 2007;104:13283- 13288.</note>
</biblStruct>

<biblStruct xml:id="b73">
	<analytic>
		<title level="a" type="main">Tyrosine kinase inhibition in diffuse large B-cell lymphoma: Molecular basis for antitumor activity and drug resistance of dasatinib</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><forename type="middle">Y</forename><surname>Lee</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="1755" to="1766" />
			<date type="published" when="2008" />
		</imprint>
	</monogr>
	<note type="raw_reference">Yang C, Lu P, Lee FY et al. Tyrosine kinase inhi- bition in diffuse large B-cell lymphoma: Molecular basis for antitumor activity and drug resistance of dasatinib. Leukemia 2008;22:1755-1766.</note>
</biblStruct>

<biblStruct xml:id="b74">
	<analytic>
		<title level="a" type="main">Modulation of 4E-BP1 function as a critical determinant of enzastaurin-induced apoptosis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">A</forename><surname>Dumstorf</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><forename type="middle">W</forename><surname>Konicek</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">M</forename><surname>Mcnulty</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Cancer Ther</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="3158" to="3163" />
			<date type="published" when="2010" />
		</imprint>
	</monogr>
	<note type="raw_reference">Dumstorf CA, Konicek BW, McNulty AM et al. Modulation of 4E-BP1 function as a critical determinant of enzastaurin-induced apoptosis. Mol Cancer Ther 2010;9:3158 -3163.</note>
</biblStruct>

<biblStruct xml:id="b75">
	<analytic>
		<title level="a" type="main">PKC beta regulates BCR-mediated IKK activation by facilitating the interaction between TAK1 and CARMA1</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Shinohara</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Yasuda</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Aiba</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Exp Med</title>
		<imprint>
			<biblScope unit="volume">202</biblScope>
			<biblScope unit="page" from="1423" to="1431" />
			<date type="published" when="2005" />
		</imprint>
	</monogr>
	<note type="raw_reference">Shinohara H, Yasuda T, Aiba Y et al. PKC beta reg- ulates BCR-mediated IKK activation by facilitating the interaction between TAK1 and CARMA1. J Exp Med 2005;202:1423-1431.</note>
</biblStruct>

<biblStruct xml:id="b76">
	<analytic>
		<title level="a" type="main">The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">R</forename><surname>Graff</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">M</forename><surname>Mcnulty</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">R</forename><surname>Hanna</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="page" from="7462" to="7469" />
			<date type="published" when="2005" />
		</imprint>
	</monogr>
	<note type="raw_reference">Graff JR, McNulty AM, Hanna KR et al. The pro- tein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts Cancer Res 2005;65:7462-7469.</note>
</biblStruct>

<biblStruct xml:id="b77">
	<analytic>
		<title level="a" type="main">The PKC{beta} selective inhibitor, enzastaurin (LY317615), inhibits growth of human lymphoma cells</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">M</forename><surname>Rossi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">D</forename><surname>Henn</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Conkling</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">106</biblScope>
			<biblScope unit="page">1483</biblScope>
			<date type="published" when="2005" />
		</imprint>
	</monogr>
	<note type="raw_reference">Rossi RM, Henn AD, Conkling R et al. The PKC{beta} selective inhibitor, enzastaurin (LY317615), inhibits growth of human lymphoma cells. Blood 2005; 106:Abstract 1483.</note>
</biblStruct>

<biblStruct xml:id="b78">
	<analytic>
		<title level="a" type="main">Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">J</forename><surname>Robertson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><forename type="middle">S</forename><surname>Kahl</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">M</forename><surname>Vose</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="1741" to="1746" />
			<date type="published" when="2007" />
		</imprint>
	</monogr>
	<note type="raw_reference">Robertson MJ, Kahl BS, Vose JM et al. Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2007;25:1741-1746.</note>
</biblStruct>

<biblStruct xml:id="b79">
	<analytic>
		<title level="a" type="main">Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Crump</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Coiffier</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><forename type="middle">D</forename><surname>Jacobsen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Oncol</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="964" to="969" />
			<date type="published" when="2008" />
		</imprint>
	</monogr>
	<note type="raw_reference">Crump M, Coiffier B, Jacobsen ED et al. Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. Ann Oncol 2008;19:964 -969.</note>
</biblStruct>

<biblStruct xml:id="b80">
	<analytic>
		<title level="a" type="main">HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Kalac</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Scotto</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Marchi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">118</biblScope>
			<biblScope unit="page" from="5506" to="5516" />
		</imprint>
	</monogr>
	<note type="raw_reference">Kalac M, Scotto L, Marchi E et al. HDAC inhib- itors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL. Blood;118:5506 -5516.</note>
</biblStruct>

<biblStruct xml:id="b81">
	<analytic>
		<title level="a" type="main">Phase II trial of standard dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab (R-CHOP) plus bevacizumab for advanced stage diffuse large B-cell (DLBCL) NHL: Southwest Oncology Group Study S0515</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Buglio</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Lemoine</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Estrella</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Abstract 591. 105. Lomon S, Fruman D. PI3K signalling in B-and T-lymphocytes: New developments and therapeutic advances</title>
		<imprint>
			<date type="published" when="2010" />
			<biblScope unit="volume">104</biblScope>
			<biblScope unit="page" from="465" to="481" />
		</imprint>
	</monogr>
	<note>Blood</note>
	<note type="raw_reference">Buglio D, Lemoine M, Estrella J et al. The allosteric AKT inhibitor MK-2206 demonstrates potent antiprolif- erative activity in lymphoma cells and synergizes with the HDAC inhibitor vorinostat. Blood;118:Abstract 3729. 104. Stopeck AT, Unger JM, Rimsza LM et al. Phase II trial of standard dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab (R- CHOP) plus bevacizumab for advanced stage diffuse large B-cell (DLBCL) NHL: Southwest Oncology Group Study S0515. Blood 2010;116:Abstract 591. 105. Lomon S, Fruman D. PI3K signalling in B-and T-lymphocytes: New developments and therapeutic ad- vances. Biochem J 2012;442:465-481. 106. Lannutti BJ, Meadows SA, Herman SE et al.</note>
</biblStruct>

<biblStruct xml:id="b82">
	<analytic>
		<title level="a" type="main">CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability</title>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">117</biblScope>
			<biblScope unit="page" from="591" to="594" />
			<date type="published" when="2011" />
		</imprint>
	</monogr>
	<note type="raw_reference">CAL-101, a p110delta selective phosphatidylinositol-3- kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 2011;117:591-594.</note>
</biblStruct>

<biblStruct xml:id="b83">
	<analytic>
		<title level="a" type="main">A phase 1 study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110D, in combination with anti-CD20 monoclonal antibody therapy and/or bendamustine in patinets with previously treated B-cell malignancies</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Leonard</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Schreeder</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Coutre</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Oncol</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<date type="published" when="2011" />
		</imprint>
	</monogr>
	<note>suppl 4):Abstract 158</note>
	<note type="raw_reference">Leonard J, Schreeder M, Coutre S. A phase 1 study of CAL-101, an isoform-selective inhibitor of phosphati- dylinositol 3-kinase P110D, in combination with anti- CD20 monoclonal antibody therapy and/or bendamustine in patinets with previously treated B-cell malignancies. Ann Oncol 2011;22(suppl 4):Abstract 158.</note>
</biblStruct>

<biblStruct xml:id="b84">
	<analytic>
		<title level="a" type="main">SF1126, a Pan-PI3K inhibitor has superior preclinical activity to CAL-101, a PI3K delta-specific inhibitor, in aggressive B-cell non-Hodgkin&apos;s lymphoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Mahadevan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><surname>Qi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Stejskal</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">118</biblScope>
			<biblScope unit="issue">2720</biblScope>
			<date type="published" when="2011" />
		</imprint>
	</monogr>
	<note type="raw_reference">Mahadevan D, Qi W, Stejskal A et al. SF1126, a Pan-PI3K inhibitor has superior preclinical activity to CAL-101, a PI3K delta-specific inhibitor, in aggressive B-cell non-Hodgkin&apos;s lymphoma. Blood 2011;118:Ab- stract 2720.</note>
</biblStruct>

<biblStruct xml:id="b85">
	<analytic>
		<title level="a" type="main">A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">E</forename><surname>Witzig</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">B</forename><surname>Reeder</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><forename type="middle">R</forename><surname>Laplant</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="341" to="347" />
			<date type="published" when="2011" />
		</imprint>
	</monogr>
	<note type="raw_reference">Witzig TE, Reeder CB, LaPlant BR et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia 2011;25:341-347.</note>
</biblStruct>

<biblStruct xml:id="b86">
	<analytic>
		<title level="a" type="main">Phase I study of the oral mammalian target of rapamycin inhibitor everolimus (RAD001) in Japanese patients with relapsed or refractory non-Hodgkin lymphoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Tobinai</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Ogura</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Maruyama</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Hematol</title>
		<imprint>
			<biblScope unit="volume">92</biblScope>
			<biblScope unit="page" from="563" to="570" />
			<date type="published" when="2010" />
		</imprint>
	</monogr>
	<note type="raw_reference">Tobinai K, Ogura M, Maruyama D et al. Phase I study of the oral mammalian target of rapamycin inhib- itor everolimus (RAD001) in Japanese patients with re- lapsed or refractory non-Hodgkin lymphoma. Int J Hematol 2010;92:563-570.</note>
</biblStruct>

<biblStruct xml:id="b87">
	<analytic>
		<title level="a" type="main">Temsirolimus has activity in non-mantle cell non-Hodgkin&apos;s lymphoma subtypes: The University of Chicago phase II consortium</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">M</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Van Besien</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Karrison</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="2534" to="2544" />
			<date type="published" when="2010" />
		</imprint>
	</monogr>
	<note>J Clin Oncol</note>
	<note type="raw_reference">Smith SM, van Besien K, Karrison T, et al. Tem- sirolimus has activity in non-mantle cell non-Hodgkin&apos;s lymphoma subtypes: The University of Chicago phase II consortium. J Clin Oncol 2010;28:4740 -4746. 112. Petrich AM, Leshchenko V, Kuo PY et al. Akt In- hibitors MK-2206 and nelfinavir overcome mTOR in- hibitor resistance in diffuse large B-cell lymphoma. Clin Cancer Res 2012;18:2534 -2544.</note>
</biblStruct>

<biblStruct xml:id="b88">
	<analytic>
		<title level="a" type="main">Multiinstitutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">E</forename><surname>Witzig</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Tang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><forename type="middle">N</forename><surname>Micallef</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">118</biblScope>
			<biblScope unit="page" from="4882" to="4889" />
			<date type="published" when="2011" />
		</imprint>
	</monogr>
	<note type="raw_reference">Witzig TE, Tang H, Micallef IN et al. Multi- institutional phase 2 study of the farnesyltransferase in- hibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas. Blood 2011;118:4882- 4889.</note>
</biblStruct>

<biblStruct xml:id="b89">
	<analytic>
		<title level="a" type="main">Cytotoxicity of farnesyltransferase inhibitors in lymphoid cells mediated by MAPK pathway inhibition and Bim up-regulation</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Ding</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Hackbarth</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">A</forename><surname>Schneider</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">118</biblScope>
			<biblScope unit="page" from="4872" to="4881" />
			<date type="published" when="2011" />
		</imprint>
	</monogr>
	<note type="raw_reference">Ding H, Hackbarth J, Schneider PA et al. Cyto- toxicity of farnesyltransferase inhibitors in lymphoid cells mediated by MAPK pathway inhibition and Bim up-regulation. Blood 2011;118:4872-4881.</note>
</biblStruct>

<biblStruct xml:id="b90">
	<analytic>
		<title level="a" type="main">The small molecule JAK1/JAK2 inhibitor INCB16562 shows single agent activity and strongly synergizes with Bcl-2 inhibitors in lymphoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Derenzini</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Lemoine</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Brighenti</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">118</biblScope>
			<date type="published" when="2011" />
		</imprint>
	</monogr>
	<note type="raw_reference">Derenzini E, Lemoine M, Brighenti E et al. The small molecule JAK1/JAK2 inhibitor INCB16562 shows single agent activity and strongly synergizes with Bcl-2 inhibitors in lymphoma. Blood 2011;118:Abstract 2731.</note>
</biblStruct>

<biblStruct xml:id="b91">
	<monogr>
		<title level="m" type="main">Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Drakos</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">R</forename><surname>Singh</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><forename type="middle">Z</forename><surname>Rassidakis</surname></persName>
		</author>
		<imprint>
		</imprint>
	</monogr>
	<note type="raw_reference">Drakos E, Singh RR, Rassidakis GZ et al. Activa- tion of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;</note>
</biblStruct>

<biblStruct xml:id="b92">
	<analytic>
		<title level="a" type="main">A novel small molecule MEK inhibitor induces cell death through a BIM-dependent mechanism in non-Hodgkins lymphoma (NHL) cell lines. Primary cells, and a human NHL xenograft model</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Evens</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Gartenhaus</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Gordon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">q32;q21</title>
		<imprint>
			<date type="published" when="2011" />
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="856" to="867" />
		</imprint>
	</monogr>
	<note>Leukemia. suppl 4): Abstract 156</note>
	<note type="raw_reference">(q32;q21). Leukemia 2011;25:856 -867. 117. Evens A, Gartenhaus R, Gordon L. A novel small molecule MEK inhibitor induces cell death through a BIM-dependent mechanism in non-Hodgkins lym- phoma (NHL) cell lines. Primary cells, and a human NHL xenograft model. Ann Oncol 2011;22(suppl 4): Abstract 156.</note>
</biblStruct>

<biblStruct xml:id="b93">
	<monogr>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Derenzini</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><surname>Iacobucci</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Brighenti</surname></persName>
		</author>
		<idno>small molecule CHK1/CHK2 inhibitor PF-0477736</idno>
		<imprint/>
	</monogr>
	<note type="raw_reference">Derenzini E, Iacobucci I, Brighenti E et al. The small molecule CHK1/CHK2 inhibitor PF-0477736</note>
</biblStruct>

<biblStruct xml:id="b94">
	<analytic>
		<title level="a" type="main">Pfizer) demonstrates single agent activity and synergizes with chemotherapy in diffuse large B-cell lymphoma</title>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">118</biblScope>
			<biblScope unit="page">2732</biblScope>
			<date type="published" when="2011" />
		</imprint>
	</monogr>
	<note type="raw_reference">Pfizer) demonstrates single agent activity and syner- gizes with chemotherapy in diffuse large B-cell lym- phoma. Blood 2011;118:Abstract 2732.</note>
</biblStruct>

<biblStruct xml:id="b95">
	<monogr>
		<title level="m" type="main">Multicenter phase II trial of MLN8237, an investigational inhibitor of aurora A kinase (AAK), in patients (PTS) with aggressive B-cell and T-cell non-Hodgkins lymphoma (NHL)</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Friedberg</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Mahadevan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Persky</surname></persName>
		</author>
		<imprint/>
	</monogr>
	<note type="raw_reference">Friedberg J, Mahadevan D, Persky D. Multicenter phase II trial of MLN8237, an investigational inhibitor of aurora A kinase (AAK), in patients (PTS) with aggres- sive B-cell and T-cell non-Hodgkins lymphoma (NHL).</note>
</biblStruct>

<biblStruct xml:id="b96">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Ann Oncol</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page">152</biblScope>
			<date type="published" when="2011" />
		</imprint>
	</monogr>
	<note>suppl 4</note>
	<note type="raw_reference">Ann Oncol 2011;22(suppl 4):152.</note>
</biblStruct>

<biblStruct xml:id="b97">
	<analytic>
		<title level="a" type="main">Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Ogura</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Hatake</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Ando</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Sci</title>
		<imprint>
			<biblScope unit="volume">103</biblScope>
			<biblScope unit="page" from="933" to="938" />
			<date type="published" when="2012" />
		</imprint>
	</monogr>
	<note type="raw_reference">Ogura M, Hatake K, Ando K et al. Phase I study of anti-CD22 immunoconjugate inotuzumab ozo- gamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma. Cancer Sci 2012;103:933- 938.</note>
</biblStruct>

<biblStruct xml:id="b98">
	<analytic>
		<title level="a" type="main">SAR3419: An anti-CD19-maytansinoid immunoconjugate for the treatment of B-cell malignancies</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><surname>Blanc</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Bousseau</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Caron</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="6448" to="6458" />
			<date type="published" when="2011" />
		</imprint>
	</monogr>
	<note type="raw_reference">Blanc V, Bousseau A, Caron A et al. SAR3419: An anti-CD19-maytansinoid immunoconjugate for the treatment of B-cell malignancies. Clin Cancer Res 2011; 17:6448 -6458.</note>
</biblStruct>

<biblStruct xml:id="b99">
	<analytic>
		<title level="a" type="main">A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Ward</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Mittereder</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Kuta</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Haematol</title>
		<imprint>
			<biblScope unit="volume">155</biblScope>
			<biblScope unit="page" from="426" to="437" />
			<date type="published" when="2011" />
		</imprint>
	</monogr>
	<note type="raw_reference">Ward E, Mittereder N, Kuta E et al. A glycoengi- neered anti-CD19 antibody with potent antibody-depen- dent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo. Br J Haematol 2011;155:426 - 437.</note>
</biblStruct>

<biblStruct xml:id="b100">
	<analytic>
		<title level="a" type="main">Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosomemediated cell death in B-cell malignancies</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><surname>Alduaij</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Ivanov</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Honeychurch</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">117</biblScope>
			<biblScope unit="page" from="4519" to="4529" />
			<date type="published" when="2011" />
		</imprint>
	</monogr>
	<note type="raw_reference">Alduaij W, Ivanov A, Honeychurch J et al. Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome- mediated cell death in B-cell malignancies. Blood 2011; 117:4519 -4529.</note>
</biblStruct>

<biblStruct xml:id="b101">
	<monogr>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><surname>Ramakrishnan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Timm</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">L</forename><surname>Haug</surname></persName>
		</author>
		<imprint/>
	</monogr>
	<note type="raw_reference">Ramakrishnan V, Timm M, Haug JL et al.</note>
</biblStruct>

<biblStruct xml:id="b102">
	<analytic>
		<title level="a" type="main">Sorafenib, a multikinase inhibitor, is effective in vitro against non-Hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin</title>
	</analytic>
	<monogr>
		<title level="j">Am J Hematol</title>
		<imprint>
			<biblScope unit="volume">87</biblScope>
			<biblScope unit="page" from="277" to="283" />
			<date type="published" when="2012" />
		</imprint>
	</monogr>
	<note type="raw_reference">Sorafenib, a multikinase inhibitor, is effective in vitro against non-Hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin. Am J Hematol 2012;87: 277-283.</note>
</biblStruct>

<biblStruct xml:id="b103">
	<analytic>
		<title level="a" type="main">Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">A</forename><surname>Barnes</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Jacobsen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Feng</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">118</biblScope>
			<biblScope unit="page">1635</biblScope>
			<date type="published" when="2011" />
		</imprint>
	</monogr>
	<note type="raw_reference">Barnes JA, Jacobsen E, Feng Y et al. Everolimus in combination with rituximab induces complete re- sponses in heavily pretreated diffuse large B-cell lym- phoma. Blood 2011;118:Abstract 1635.</note>
</biblStruct>

<biblStruct xml:id="b104">
	<analytic>
		<title level="a" type="main">Safety and efficacy of the novel combination of panobinostat (LBH589) and everolimus (RAD001) in relapsed/refractory Hodgkin and non-Hodgkin lymphoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Younes</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Copeland</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">A</forename><surname>Fanale</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">118</biblScope>
			<date type="published" when="2011" />
		</imprint>
	</monogr>
	<note>Abstract 3718</note>
	<note type="raw_reference">Younes A, Copeland A, Fanale MA et al. Safety and efficacy of the novel combination of panobinostat (LBH589) and everolimus (RAD001) in relapsed/refrac- tory Hodgkin and non-Hodgkin lymphoma. Blood 2011; 118:Abstract 3718.</note>
</biblStruct>

<biblStruct xml:id="b105">
	<analytic>
		<title level="a" type="main">Combination of NVP-BEZ235 and enzastaurin on B-cell lymphoma cell lines: An effective therapeutic strategy</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Civallero</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Cosenza</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Pozzi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">118</biblScope>
			<date type="published" when="2011" />
		</imprint>
	</monogr>
	<note type="raw_reference">Civallero M, Cosenza M, Pozzi S et al. Combina- tion of NVP-BEZ235 and enzastaurin on B-cell lym- phoma cell lines: An effective therapeutic strategy. Blood 2011;118:Abstract 2719.</note>
</biblStruct>

<biblStruct xml:id="b106">
	<analytic>
		<title level="a" type="main">Obatoclax interacts synergistically with the irreversible proteasome inhibitor carfilzomib in GC-and ABC-DLBCL cells in vitro and in vivo</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Dasmahapatra</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Lembersky</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">P</forename><surname>Son</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Cancer Ther</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="1122" to="1132" />
			<date type="published" when="2012" />
		</imprint>
	</monogr>
	<note type="raw_reference">Dasmahapatra G, Lembersky D, Son MP et al. Obatoclax interacts synergistically with the irreversible proteasome inhibitor carfilzomib in GC-and ABC- DLBCL cells in vitro and in vivo. Mol Cancer Ther 2012;11:1122-1132.</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
